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ABSTRACT 
 
Novel Mechanisms Controlling the Expression of the 
Antidiabetic Hepatokine Fibroblast Growth Factor 21 
 
Kimberly M. Alonge 
 
 The incidence of obesity has increased at an alarming rate during the past thirty years.  
Current therapies for the treatment and prevention of obesity and metabolic syndrome are 
ineffective and/or produce undesirable side effects.  Fibroblast growth factor 21 (FGF21) is a 
liver derived hormone that mediates adaptive changes in hepatic glucose and lipid metabolism by 
elevating energy expenditure and reducing lipid storage.  Pharmacological administration of 
FGF21 analogs in both animal and human models induces striking reversals of obesity and type 
2 diabetes.  However, the activity of FGF21 analogs exhibit short half-lives in blood circulation 
and are unsuitable for current treatment.  Therefore it is imperative that mechanisms mediating 
the activity of endogenous FGF21 be understood.  
FGF21 expression is enhanced during starvation, high-fat low-carbohydrate (HF-LC) 
ketogenic diet, type 2 diabetes, and obesity.  Starvation induces a high glucagon to insulin 
metabolic hormone ratio in the portal vein.  Type 2 diabetics also exhibit chronically high 
glucagon to insulin ratios in blood circulation.  Furthermore, infusions with high glucagon, low 
insulin hormone concentrations increase the production and secretion of splanchnic FGF21 in 
man.  The mechanisms by which glucagon and insulin work cooperatively to selectively increase 
hepatic FGF21 expression and secretion is currently unknown.  
 To understand the molecular mechanisms mediating the induction of FGF21 expression 
in the liver, we recapitulated the conditions of starvation in primary rat hepatocytes by treating 
cultures with glucagon and insulin using concentrations similar to that observed in the portal vein 
during starvation.  We then utilized a reverse genetics approach to identify two conserved amino 
acid response elements (AAREs) on the FGF21 promoter that were critical in mediating the 
effects of starvation on FGF21 gene expression.  We further defined the transcription factor, 
activating transcription factor 4 (ATF4), as the primary transcription fact responsible in 
stimulating FGF21 gene transcription during glucagon plus insulin treatment.  We then 
characterized the glucagon and insulin signaling pathways mediating the cooperative actions of 
glucagon plus insulin on FGF21 gene expression using loss-of-function and gain-of-function 
techniques, and determined that both the PI3K/Akt/mTORC1 and cAMP/PKA signaling 
pathways were responsible for inducing FGF21 expression.  Lastly, we applied these novel 
findings to further define the mechanisms other stimuli, such as chenodeoxycholic acid (CDCA), 
employ to induce FGF21 expression.  Understanding the fundamental mechanisms by which 
these two hormones work together provided the scientific community with in-depth knowledge 
on pathways mediating the endogenous expression of hepatic FGF21 and also identified 
additional targets for drug development for the treat of metabolic syndrome. 
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Chapter One 
 
LITERATURE REVIEW 
 
 
 
INTRODUCTION 
 
 
Obesity is a state of metabolic dysregulation that targets both children and adults alike 
and is the gateway illness to a lifetime of medical and financial burden.  Alarmingly, the 
prevalence for type 2 diabetes (T2D) in children and adolescents have dramatically increased by 
30.5% from 2001-2009 (1).  The increase in obesity and T2D diagnoses in children suggest 
future generations of Americans will continue to be burdened with weight-related medical 
complications for much of their lives.  Currently, over 30% of adults in the US are classified 
obese and this percentage is expected to soar to 42% by 2030 (2).   
The high-fat, high protein, and high-carbohydrate “Western diet” of today is affordable, 
conveniently obtained, and encourages nutrient consumption in dietary excess (3).  The 
consumption of daily nutrient surpluses combined with an ever-increasing sedentary behavior 
and poor education contributes to the increasing rates of obesity throughout the nation.  Obesity 
contributes to the development of metabolic syndrome and secondary diseases states such (e.g. 
cardiovascular disease and T2D) (4).  T2D is a metabolic disease that results from lifestyle 
choices, as well as an individual’s genetics, and is associated with obesity, insulin deficiency, 
and selective insulin resistance in peripheral metabolic tissues (5).  Obesity directly contributes 
to the development of over half of T2D cases, therefore the majority of individuals diagnosed 
with T2D have been found to be either obese or overweight (6).  Although T2D is most often 
associated with obesity and insulin resistance, it can also further develop into additional medical 
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complications such as limb neuropathy, kidney disease, stroke, and depression (4).  The effects 
of obesity, and secondary diseases resulting from obesity, is predicted to coast Americans $147 
billion dollars annually in medical expenses (7).   
One way to reverse the effects of obesity and T2D is to first target patient weight-loss 
through diet and exercise programs.  Unfortunately, up to 98% of individuals who initially lose 
weight through these traditional methods gain the weight back within 2 years (8).  The lack of 
success in traditional weight loss strategies has produced a much-anticipated market for 
alternative weight loss therapies.  Throughout the years a slew of over-the-counter and 
prescription drugs, which falsely claim to increase weight-loss of the consumer without changes 
in diet and exercise, have been introduced into the public market (9,10).  Meanwhile, current 
drug therapies that have been shown to successful treat and prevent obesity and T2D become 
ineffective overtime and/or produce undesirable side effects (Tables 1.1 and 1.2).  The lack of 
safe and reliable weight-loss treatments to counteract today’s obesity epidemic has pressured the 
medical field to identify novel targets for the development of anti-obesogenic and anti-diabetic 
therapies.   
Fibroblast growth factor 21 (FGF21) is an atypical member of the fibroblast growth 
factor family that lacks the ability to bind to heparin sulfate proteoglycans, allowing it to escape 
the extracellular matrix and function in an endocrine-like manner (11,12).  FGF21 acts on 
peripheral and central metabolic tissues to mediate adaptive glucose and lipid metabolism by 
inducing fatty acid oxidation while decreasing fatty acid synthesis and triglyceride storage (12-
17).  Most importantly, administration of FGF21 analogs dramatically increases weight loss and 
decreases characteristics of T2D in rodent and human models (18,19).  Currently, little is known 
about the endogenous regulation of FGF21 expression.  Understanding the mechanisms 
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mediating the endogenous production of FGF21 will help identify novel pharmacological targets 
for the production of successful weight-loss therapies in the future. 
 
 
Table 1.1. Current Therapy Treatments for Obesity 
Treatment Side Effects 
Sibutramine  
(Serotonin/Norepinephrine Re-uptake Inhibitor) 
 
Heart attack, stroke (20) 
Orlistat GI side effects, liver disease (21) 
 
Lorcaserin Hydrochloride  
(Serotonin 2C Receptor Agonist) 
 
Headache, cancer, GI side effects (22) 
Weight Loss Surgery Infection, bowel tearing, vitamin/mineral deficiency, stenosis, 
vomiting, ulceration, bleeding, splenic injury, death (23) 
 
http://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis- treatment/ treatment/t xc-20169988 
 
 
 
 
Table 1.2. Current Therapy Treatments for Type 2 Diabetes 
Treatment Side Effects 
 
Metformin  
(Glucophage, Glumetza) 
 
Resistance, nausea, GI side effects (24) 
Insulin Therapy 
 
Hypoglycemia, weight gain (25) 
 
Insulin Sensitizing Agents (Sulfonylureas, Meglitinides, 
Thiazolidinediones) 
 
Hypoglycemia, weight gain, heart failure (26) 
Glucagon-like Peptide 1 Receptor Agonists Nausea, pancreatitis, GI issues (27) 
 
Dipeptidyl Peptidase 4 Inhibitors GI side effects, flu-like symptoms,  
skin reactions, heart failure (28) 
 
Sodium/Glucose Transporter 2 Inhibitors Yeast infections, UTI, hypotension (29) 
 
https://www.nhlbi.nih.gov/health/health-topics/topics/obe/treatment  
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PHARMACOLOGICAL MODULATION OF FGF21 SIGNLAING 
 
Recombinant FGF21 Protein and FGF21 Analog Therapy 
Administration of recombinant FGF21 protein in obese and T2D animal models increases 
energy expenditure and decreases adiposity, weight, and blood TG (30,31).  FGF21 recombinant 
protein administration also decreases blood glucose, increases insulin sensitivity, and diminishes 
arterial plaque formation (31-36).   Interestingly, some studies show recombinant FGF21 protein 
and FGF21 analog administration in mice causes a marked decrease in food intake and increased 
weight loss (19,37), while in other studies employing FGF21 treatment increased weight loss but 
did not decrease food intake (38-40).  These results suggest FGF21 functions by increasing fatty 
acid β-oxidation and energy expenditure, but are inconclusive as to whether FGF21 mediates 
overall energy intake.  
Recently, interest in FGF21 as a weight-loss target has intensified with reports of 
successful phase 1 clinical trials in obese and T2D human subjects (18,19).  In these trials FGF21 
exhibited a strong anti-obesogenic, anti-diabetic effects after being injected into human subjects.  
For example, treatment using the FGF21 analog PF-05231023 improved the circulating lipid 
profile and decreased body weight in humans (19).  Disadvantages to using a recombinant 
FGF21 protein stem from its short half-life in blood circulation in addition to the tendency for 
the recombinant protein to aggregate during synthesis (41-44).   
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Targeting and Activating the FGF-Receptor 
FGF21 signals through the fibroblast growth factor receptor isoform 1c (FGFR1c) 
(45,46).   Binding of FGF21 to FGFR1c requires the presence of the co-activator β-Klotho, a 
type I transmembrane protein (47).  Prior to ligand binding, β-Klotho must first bind to FGFR 
and form a FGFR/Klotho heterodimer (Fig. 1.1A) (48).  After heterodimerization, two 
FGFR/Klotho heterodimers homodimerize to form an inactive tetramer (Fig 1.1B).  FGF21 
activates the FGFR/Klotho tetramer by interacting its C-terminus with β-Klotho and its N-
terminus with the FGFR, thus forming a fully active FGF receptor complex (Fig. 1.1C) (47).  
 
	
 
 
Figure 1.1. FGF21 signals through FGFR1c.  (A) Co-activator β-Klotho first binds to the 
FGFR and forms a FGFR/Klotho heterodimer.  (B) Two FGFR/Klotho heterodimers 
homodimerize to form an inactive tetramer.  (C) FGF21 activates the FGFR/Klotho 
tetramer by interacting its C-terminus with β-Klotho and its N-terminus with the FGFR. 
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Another approach to increase FGF21 signaling without administering a recombinant 
FGF21 protein or FGF21 analog is to target and activate the FGFR1c complex independently of 
FGF21 ligand binding (49).  A single dose injection of RM1Ab, an antibody designed to target 
and activate the FGFR1, reduces hyperglycemia and hepatosteatosis and improves 
hyperinsulemia and hyperlipidemia in obese diabetic mice (50).  Unexpectedly, RM1Ab targets 
and activates FGFR1 in the absence of β-Klotho, which leads to an inappropriate activation of 
the receptor across all tissues types expressing FGFR1.  To overcome this promiscuity, avimers 
were designed to recognize and bind to the FGFR1/β-Klotho tetramer distinct from the unbound 
FGFR1.  Although these artificial proteins display similar activities to that of endogenous FGF21 
ligand (51),  they too exhibit high immunogenicity and quickly lose activity in blood circulation. 
One alternative to increasing FGF21 signaling independently of recombinant FGF21 
protein injections or molecular activation of receptor complexes, is to target and increase the 
endogenous production of FGF21 within the body.  Markan et al. (2014) proved the liver is the 
main source of circulating FGF21 protein (52).  Tailoring to the discovery that circulating 
FGF21 is liver derived, the remainder of this review aims to provide insights into the 
physiological conditions and metabolic pathways mediating the endogenous expression of 
FGF21 in the liver.  
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TISSUE-SPECIFIC FGF21 SIGNALING 
 
Tissue Expression of β-Klotho 
As previously mentioned, the prerequisite for β-Klotho to induce higher order ligand-
independent receptor complex formation prior to the binding of the FGF21 ligand is crucial (Fig. 
1.1).  Due to the strict requirement of β-Klotho in FGFR1c/FGF21 signaling, it is widely 
believed the actions of FGF21 are restrained to the selective metabolic tissues that 
simultaneously express both the FGFR1c receptor isoform and the β-Klotho co-activator 
(45,46,48).  Surprisingly, although circulating FGF21 protein expression is liver derived, the 
liver does not express the FGFR1c isoform at physiologically relevant levels (52,53).  It can be 
concluded that, since the liver does not express FGFR1c, FGF21 does not directly signal back 
upon its tissue of origin.  Samms et al. (2016) showed that mice overexpressing adipocyte β-
Klotho leads to enhanced FGF21 signaling, energy expenditure, thermogenesis, and weight loss 
under high fat dietary conditions (54).  In contrast, mice overexpressing hepatocyte β-Klotho 
were unable to counteract the negative effects of high fat dietary conditions. These results 
support the theory that FGF21 protein expression is liver derived but signals distinct from the 
liver at FGFR1c/β-Klotho expressing tissues to mediate the anti-diabetic, anti-obesogenic effects 
of FGF21 in the body. 
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FGF21 Signaling in Adipose Tissue 
White adipose tissue is highly enriched for the FGFR1c isoform (46,55).  In adipocytes, 
activation of the FGFR1 increases downstream phosphorylation of extracellular signal-regulated 
kinase (ERK), fibroblast growth factor receptor substrate 2 (FRS2), protein kinase B (Akt), and 
signaling transducer and activator of transcription 3 (Stat3) (49,56).  FGF21 decreases circulating 
non-esterified fatty acids (NEFAs) by increasing uptake in white adipose tissue and decreases 
circulating glucose levels by increasing disposal into brown adipose tissues (52,57).  Knockout 
of FGFR1 signaling in adipocytes increases adipose lipolysis that results in elevated circulating 
serum NEFAs, TG, and increasing hepatic steatosis (58).  Interestingly, adipose specific FGFR1-
null mice also correlate to enhanced FGF21 expression in the liver, presumably to compensate 
for the repressed FGFR signaling in the adipose tissue.  Together these results suggest that 
circulating intermediate metabolites, such as NEFAs, produced from adipocyte lipolysis act upon 
the liver to elevate expression of hepatic FGF21 and that the increase in FGF21 protein 
expression acts as a compensatory mechanism to halt adipose lipolysis and reverse hepatic 
steatosis.  
Adiponectin, an anti-inflammatory, lipid-lowering adipokine, mediates the physiological 
effects of FGF21 in the body.  Adiponectin acts upon blood vessels to decrease low density 
lipoproteins (LDL), cholesterol, and triglycerides while simultaneously increasing the production 
of very low density lipoprotein (VLDL) catabolism (59).  Mice fed a high fat diet increase 
circulating FGF21 expression, stimulate adiponectin secretion from adipocytes, lowers 
circulating lipids levels, and increases whole body insulin sensitivity (49,60).  Meanwhile, 
adiponectin-null mice are resistant to the lipid lowing effects produced by FGF21 
pharmacological administration, suggesting the majority of FGF21’s actions are governed 
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through downstream adiponectin secretion (61,62).  In humans, atherosclerosis increases both 
circulating FGF21 and adiponectin protein concentrations (34).  Adiponectin protects against 
atherosclerosis by reducing oxidative stress, lesion formation, and circulating triglycerides (63).  
Overall, FGF21 lowers circulating lipids and protects against heart disease and obesity through 
the actions of adiponectin. 
 
FGF21 Signaling in Central Metabolism 
 Another tissue highly enriched for both the FGFR1c isoform and co-activator β-Klotho is 
the brain.  In situ hybridization studies show β-Klotho is selectively enriched in the hypothalamic 
suprachiasmatic nucleus (SCN) as well as the hindbrain dorsal vagal complex (DVC), while 
FGFR1c is broadly expressed throughout the central nervous system (17).  Selective brain 
specific knockout of β-Klotho in the SCN/DVC impairs the ability of transgenic FGF21 mice 
overexpressing hepatic FGF21 to resist weight gain, induce thermogenesis, and increase energy 
expenditure when placed on a high fat diet (64).  Interestingly, patients with hypothyroidism 
show decreased FGF21 expression in serum (65).  These results suggest the central nervous 
system not only plays a crucial role in mediating the metabolic actions of FGF21 in the body, but 
also may mediate FGF21 expression in general.  
 In addition to FGF21’s lipid lowering actions, FGF21 also plays an important role in 
feeding behaviors.  Overexpression of endogenous hepatic FGF21 protein expression, as well as 
exogenous administration of recombinant FGF21 protein, decreases sugar preference and meal 
size in mice (37,66).  In contrast, knockout of FGF21 protein expression increases sugar choice 
and food intake.  Furthermore, knockout of β-Klotho expression in the paraventricular nucleus 
(PVN) decreases FGF21 signaling and abolishes the ability of FGF21 to decrease sweet 
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preference in mice.  Overall, these finding suggest FGF21 signals in the central nervous system 
to mediate feeding behaviors.  
 FGF21 also acts upon the central nervous system to regulate bodily functions not directly 
related to metabolism.  For example, FGF21 decreases kisspeptin hormone expression in the 
hypothalamus, which decreases gonadotropin-releasing hormone (GnRH) secretion and increases 
female infertility in mice (67,68).  FGF21 also increases glucocorticoid levels, decreases 
physical activity, and alters circadian behavior (17,69,70).  Of particular interest, overexpression 
of FGF21 markedly increases lifespan in rodent models (39,71).  Taken together, FGF21 plays a 
critical role in mediating a variety of nutritional and physiological adaptive responses by 
signaling through the central nervous system. 
 
FGF21 Resistance 
 Obese mice and humans exhibit chronic elevated levels FGF21 protein expression in 
blood circulation and mRNA abundance in the liver (16,56,72).  This observation directly 
contradicts the predicted anti-diabetic, anti-obesogenic actions of FGF21 within the body.  The 
paradoxical increase in FGF21 protein expression in blood circulation in obese and T2D 
individuals may be related to the development of FGF21 “resistance” within the body.  This 
resistance may originate at the FGF21-FGFR1c signaling interface, or it may occur further 
downstream of FGF21 receptor signaling.  In support FGF21 resistance, obese patients show 
increased circulating FGF21 protein expression in serum but decreased adiponectin expression 
(61).  Since adiponectin mediates the specific actions of FGF21 within the body, the resistance in 
obese individuals may be due to the inability of FGF21-FGFR1c signaling pathway to stimulate 
adiponectin secretion in adipocytes.  Alternatively, FGF21 may still be able to successfully 
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signal through FGFR1c in adipose tissue, but adiponectin synthesis or secretion is repressed by 
additional unknown mechanisms.  
Additional evidence supporting the idea that FGF21-FGFR1c receptor signaling is 
impaired in metabolic disease conditions originate from studies examining β-Klotho protein 
expression in response to obesity.  Obese mice exhibit increased c-Jun N-terminal kinase (JNK) 
activity in adipocytes, which decreases β-Klotho protein expression, FGFR/Klotho heterodimer 
formation, and corresponding downstream FGF21 signaling (56).  Db/db mice also exhibit 
repressed β-Klotho protein expression and FGF21 signaling, but also show increased hepatic 
FGF21 mRNA abundance and circulating FGF21 protein expression presumably due to an 
overcompensation effect (73).  Taken together, these results suggest FGF21 resistance originates 
from repressed β-Klotho protein expression and impaired FGFR1c receptor signaling. 
 Most recently, another novel theory exploring an alternative mechanism for FGF21 
resistance by protein cleavage has emerged.  Both human and murine FGF21 proteins are 
cleaved by dipeptidyl peptidase-IV (DPP-IV) at 2 specific proline locations (Pro2 and Pro4) at 
the N-terminus of the FGF21 peptide (44).  Cleavage at these two proline residues does not 
affect the activity of circulating FGF21 protein.  Unexpectedly, the cleavage of a third proline 
residue at the C-terminus (Pro171), found exclusively in the human FGF21 peptide, has been 
identified.  Pro171 is cleaved by a newly discovered serine proteinase, fibroblast activating 
protein (FAP), which cleaves and inactivates the FGF21 protein (43).  Interestingly, inhibiting 
FAP activity increases circulating FGF21 protein expression in non-human primates (43).  
Further investigation is needed to further identify whether dietary conditions affect the activity, 
or abundance, of circulating FAP and sequential inactivation of FGF21 protein. 
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PHYSIOLOGICAL EXPRESSION OF ENDOGENOUS FGF21  
 
Starvation and PPARα  
FGF21 acts as a nutritional adapter during times of extreme nutritional stress.  For 
example, the nutritional stress induced by long-term fasting and starvation robustly stimulates 
FGF21 gene transcription in the liver and FGF21 protein secretion into the blood circulation (74-
76).  During starvation, FGF21 functions to increase factors involved in gluconeogenesis, fatty 
acid oxidation, ketogenesis, and gluconeogenesis while simultaneously repressing those involved 
in lipogenesis (13,16,53,56).  Interestingly, overexpression of FGF21 in mice does not increase 
glycogenolysis, suggesting FGF21 plays a role in mediating late fasting responses after glycogen 
storages have already been depleted (77).  In agreement with this argument, circulating FGF21 
protein expression in humans is decreased during the early fasting period but robustly increased 
after long-term (10 day) fasting conditions (78).  
Starvation also enhances lipolysis in adipocytes to breakdown lipids for energy (79). 
Lipids, stored as TG in adipose tissue, are broken down into NEFA and glycerol (Fig. 1.2) (79).  
NEFAs travel from the adipose tissue to peripheral metabolic tissues where they are utilized as 
cellular energy sources when blood glucose concentrations are low (80).  In the liver, NEFAs 
undergo mitochondrial oxidation and form acetyl-CoA, a substrate utilized in ketone body 
production (ketogenesis), or further oxidized in the tricarboxylic acid cycle (TCA) to form ATP 
for glucose production (gluconeogenesis) (Fig. 1.2) (81,82).  Meanwhile, the free glycerol 
released by TG lipolysis can also be used as a substrate in gluconeogenesis to promote glucose 
production.  Both ketone bodies and glucose are used as energy sources in peripheral tissues 
during starvation (83).  Infusion of NEFAs increases circulating FGF21 protein concentration in  
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Figure 1.2. Fates of lipid intermediates during starvation.  Breakdown of TAGs in 
adipocytes releases free fatty acids (FFA) and glycerol which are transported to peripheral 
tissues for energy sources.  In the liver, FFAs are oxidized in the mitochondria to produce 
acetyl-CoA, a substrate for ketogenesis, tricarboxylic citric acid cycle (TCA), and 
gluconeogenesis.  Glycerol is also a substrate for gluconeogenesis.  Both ketone bodies and 
glucose are used as energy sources in peripheral tissues during starvation. 
 
human and animal models (Fig. 1.3) (78,84,85).		These results suggest hepatic FGF21 expression 
is stimulated during conditions of starvation where adipocytes lipolysis increases circulating 
NEFA concentrations.  Interestingly, anorexic individuals are unable to induce FGF21 
expression during starvation, presumably due to their low body fat concentrations (56).  
In addition to being substrates for ketogenesis and gluconeogenesis, long-chain fatty 
acids are also endogenous ligands for the transcription factor peroxisome proliferator-activated 
receptor alpha (PPARα) (86).  Ligand activated PPARα heterodimerizes with the retinoid X 
receptor (RXR) and binds to PPAR-response elements (PPREs) on target gene promoters and 
increases transcription of genes involved in fatty acid metabolism and lipoprotein formation 
(87,88).  Notably, PPARα enhances hepatic FGF21 gene transcription by heterodimerizing with 
RXR and localizing to an upstream PPRE located on the FGF21 promoter (Fig. 1.3) (88-90).  
Chemical activators of PPARα, such as fenofibrate and GW7647, also increase FGF21 
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expression in both rodents and human models (69,89,91-94).  Benzafibrate, a lipid lowering 
drug, increases PPARα activity and stimulates FGF21 expression (69).  Interestingly, the 
stimulatory effect of starvation on FGF21 gene expression is greatly reduced, but not completely 
abolished, in PPARα knockout mice (89,91,94). Since PPARα-null mice are unable to 
completely suppress the effects of starvation on FGF21 gene expression, additional signaling 
pathways may play a role in mediating the nutritional regulation of FGF21 during fasting 
conditions. 
 
Overnutrition, T2D, and ChREBP  
As previously stated, FGF21 acts as a metabolic adapter during conditions of extreme 
nutritional stress.  In contrast to starvation, a second type of extreme nutritional stress in the liver 
occurs during overnutrition.  Circulating FGF21 protein levels are elevated in obese and T2D 
animal and human models suggesting that overnutrition and obesity related diseases also enhance 
FGF21 gene activity (Fig 1.3) (95,96).  For example, overexpression or administration of FGF21 
decreases NEFAs, triglycerides, and serum glucose in mice fed a high fat, obesogenic diet 
(57,97,98).  FGF21 also signals in the CNS to increase sympathetic nerve activity, peripheral 
thermogenesis, and browning of adipose tissue through the actions of uncoupling protein-1 
(UCP-1) in obese animals (64,74).  
Obesogenic diets increase glucose availability to peripheral metabolic tissues (99).  
Glucose increases the activity of glucokinase and protein phosphatase 2a which results in the 
dephosphorylation, nuclear translocation, and increased transcriptional activation of the 
carbohydrate response element binding protein (ChREBP).  ChREBP is a transcription factor 
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that binds to carbohydrate response elements (ChoREs) on target metabolic promoters and 
controls 50% of lipogenesis by regulating glycolytic and lipogenic genes (100-104). 
 
 
 
Figure 1.3. Physiological Modulation of Endogenous FGF21 Expression in the Liver. 
Starvation increases the circulation of FFA.  Long-chain FFAs are endogenous ligands for 
PPARα.  Ligand activated PPARα dimerizes with the RXR and binds to the upstream 
PPRE site on the FGF21 promoter to enhance gene transcription.  Overnutrition increases 
circulating glucose levels.  Glucose increases the transactivation of ChREBP, a 
transcription factor that binds to a downstream ChoRE sites on the FGF21 promoter to 
stimulate FGF21 gene transcription.  High-fat, low-carbohydrate keotgenic diets increase 
the hepatic circulation of bile acids.  Chenodeoxycholic acid activates FXR.  Ligand 
activated FXR heterodimerizes with RXR and binds to an upstream FXRE on the FGF21 
promoter to stimulate gene transcription.  Unfolded proteins in the lumen of the ER induce 
the UPR. Activation of the downstream IRE1α arm of the UPR induces splicing of XBP1.  
Spliced and activated XBP1s binds to the downstream ERSE on the FGF21 promoter to 
stimulate gene transcription.  Activation of the downstream PERK arm of the UPR leads to 
the phosphorylation of eIF2α and induced translation of ATF4.  ATF4 is a transcription 
factor that binds to both upstream and downstream AAREs on the FGF21 promoter to 
stimulate gene transcription.  
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ChREBP activity is stimulated by glucose independently of insulin and functions to convert 
excess circulating glucose into triglycerides in the liver and adipose for storage (105,106).  In 
primary hepatocytes, glucose induces transactivation of ChREBP to a downstream ChoRE site 
located on the FGF21 promoter and stimulates FGF21 gene transcription (Fig. 1.3) (37,107).  It 
is speculated that enhanced glucose availability during overnutrition, obesity, and T2D increases 
ChREBP activity and FGF21 gene transcription.  Although in vitro data suggests ChREBP is a 
mediator of FGF21 promoter activity, in vivo studies examining carbohydrate re-feeding and 
resulting FGF21 expression are conflicting.  Palou et al. (2008) showed a marked decrease in 
hepatic FGF21 mRNA abundance after carbohydrate re-feeding in mice (76), while other studies 
showed an increase in hepatic FGF21 mRNA after carbohydrate re-feeding (37,108).  The 
mechanisms regulating FGF21 expression during carbohydrate re-feeding are not yet clear and 
likely involve multiple pathways distinct from ChREBP.  For example, carbohydrate re-feeding 
decreases PPARα signaling in the liver and may account for the decrease in FGF21 expression 
observed in some studies (109).  On the contrary, a high fat diet containing carbohydrates 
increases circulating dietary fatty acids, hepatic PPARα activity, and FGF21 gene expression 
which may account for the increase in FGF21 expression in those studies (110).  It is no surprise 
that differing dietary compositions between studies play a crucial role in regulating FGF21 
expression. These results suggest additional signaling pathways independent of PPARα may 
mediate overnutrition, obesity, and T2D induction of hepatic FGF21 expression. 
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Bile Acids and FXR 
Bile acids are amphipathic, detergent-like molecules stored in the gallbladder that 
function to solubilize cholesterol and lipids in the intestines (111).  Chenodeoxycholic acid 
(CDCA) and cholic acid make up 80% of the bile acid composition in humans (112).  During 
feeding, the duodenum secretes cholecystokinin (CCK) which signals to the gallbladder, the 
primary storage location for bile acids (113).  In response to CCK, the gallbladder contracts and 
secretes bile acids into the large intestines where they form mixed micelles with cholesterol and 
phospholipids to solubilize dietary nutrients (111,114).  After feeding, ~95% of bile acids are 
reabsorbed at the distal ileum and enter the enterohepatic circulation where they pass through the 
liver before being recycled back into the gallbladder (114,115).  Dietary fats increase the 
production of CCK and consecutive secretion of bile acids (116,117).   Obese and T2D humans 
and mice exhibit a correlation between increased CDCA synthesis and bile acid pool size with 
circulating FGF21 protein expression (Fig. 1.3) (112,118-120).  In addition, humans with biliary 
atresia also exhibit increased serum and hepatic FGF21 expression (121).   
In particular, CDCA is a potent activator of FGF21 mRNA gene transcription in primary rat 
hepatocytes (Fig. 1.3) (122).  CDCA activates the bile acid nuclear receptor, farnesoid X 
receptor (FXR), which dimerizes with RXR and binds to a upstream farnesoid X receptor 
response element (FXRE) on the FGF21 promoter (Fig. 1.3) (122).  Ablation of FXR gene 
partially represses the ability of a ketogenic diet to induce hepatic FGF21 mRNA abundance and 
serum FGF21 protein concentrations (122).  These results suggest that a high-fat, low-
carbohydrate ketogenic diet induces the production of CCK, secretion of bile acids, and 
enterohepatic circulation of bile acids through the liver where they stimulate FXR/RXR 
heterodimerization and induce hepatic FGF21 gene transcription.  Since FXR-null mice do not 
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completely repress the ability of ketogenic diet to increase FGF21 expression in the liver, other 
mechanisms independent of FXR activation are required to induce FGF21 gene expression 
during a high-fat, low-carbohydrate ketogenic diet. 
 
ER Stress  
Circulating FGF21 protein expression is increased in additional, non-dietary mediated 
states of cellular stress including patients with chronic kidney disease, viral infection, and 
systematic inflammatory response syndrome (SIRS) (123-125).  Even mechanical stress, such as 
ischemic reperfusion injuries in liver transplants, endurance exercise, and wound healing, is 
correlates with an increase in FGF21 expression (126-128).  Due to the wide range stress stimuli, 
nutritional and cellular, that induce expression and circulation of FGF21, FGF21 is now widely 
accepted as a general stress induced factor (49,129). 
The endoplasmic reticulum (ER) is a versatile organelle that plays a critical role in 
transmembrane lipid and protein biosynthesis (130).  Secretory and transmembrane proteins are 
translated by ribosomes on the cystolic surface of the ER but translocate into the lumen of the 
ER for proper folding, stabilization, and modification.  In addition to protein biosynthesis, the 
ER also contains a calcium reservoir used for both storage and signaling.  The calcium pool 
within the ER lumen is 3-4 fold higher compared to that of the cytosol, and the ER is highly 
sensitive to lumen calcium perturbations.  For example, calcium dysregulation and/or protein 
misfolding within the ER lumen can activate the unfolded protein response (UPR) if equilibrium 
is breached (131).  Overnutrition produces an excess in glucose, insulin, NEFA, and cytokines 
that have been shown to increase protein misfolding/aggregation and induce ER stress and 
activate the UPR (132).  The three branches of the UPR consists of inositol requiring enzyme 1 
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alpha (IRE1α), activating transcription factor 6 (ATF6), and protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) (Fig. 1.4) (133).   
During basal conditions, when ER stress is low, the molecular chaperone binding 
immunoglobin protein (BiP/GRP78) binds to and inactivates the three arms of the UPR (Fig. 1.4) 
(130,134).  When ER stress is induced, either through chemical or endogenous manipulations, 
unfolded proteins accumulate within the lumen of the ER and bind BiP.  The binding of unfolded 
proteins to BiP sequesters the protein away from IRE1α, ATF6, and PERK.  Once unbound from 
BiP, the three arms of the UPR become active and are able to signal to downstream pathways.  
Unbinding of BiP from IRE1α causes IRE1α to oligomerize, autophosphorylate, and activate 
downstream signaling pathways (135).  Oligomerization and autophosphorylation of IRE1α 
conformationally changes the protein’s structure, resulting in increased RNase activity of the 
protein oligomer.  IRE1α splices the UPR transcription factor, x-box binding protein 1 (XBP1), 
at two separate sites resulting in the excision of a small intron and yielding a functional, 
activated transcriptional factor (XBP1s) (136).   
Splicing of XBP1 leads to enhanced binding of XBP1s at UPR elements (UPRE) or ER-
stress response elements (ERSE) located on target promoters of cytoprotective genes involved in 
the UPR and ER-assisted degradation (ERAD) pathways (137,138).  For example, tunicamycin 
treatment in hepatocytes induces IRE1α activation, XBP1 splicing, and transactivation of XBP1s 
to a downstream ERSE located on the FGF21 promoter, leading to stimulated FGF21 gene 
transcription during ER stress (Fig. 1.3) (139).  Activation of IRE1α can also induce apoptosis 
by activating additional downstream signaling pathways including apoptotic-signaling kinase 1 
(ASK1), JNK, and p38 mitogen-activated protein kinase (p38 MAPK) (Fig. 1.4) (140).  A third 
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pathway IRE1α mediates is the regulated IRE1-dependent decay (RIDD) pathway. RIDD is a 
specialized pathway used to target and degrade selective UPR mRNAs (Fig. 1.4) (141,142). 
 
Figure 1.4.  The three arms of the unfolded protein response.  During conditions of low 
cellular stress, BiP binds to and inactivates IRE1α, ATF6, and PERK.  During conditions 
of high ER stress, unfolded proteins accumulated within the lumen of the ER and sequester 
BiP from the three arms, thus leading to the activation of the UPR.  (A) IRE1α 
oligomerizes, autophosphorylates, and activates its RNase domain.  IRE1α splices XBP1, a 
transcription factor that, once spliced, binds to ERSE and URSE elements on target 
promoters to induce gene transcription for UPR genes.  IRE1α can also activate RIDD 
mediated mRNA degradation and JNK mediated apoptosis.  (B) ATF6 is cleaved from the 
ER membrane and further processed in the Golgi.  After cleavage in the Golgi, ATF6 
travels to the nucleus and stimulates gene transcription for UPR chaperones.  (C) PERK 
oligomerizes, autophosphorylates, and phosphorylates the downstream target eIF2α.  
eIF2α decreases global translation while increasing translation of selective UPR chaperones 
and transcription factors such as ATF4.  ATF4 is a transcription factor that binds to target 
genes and induces gene transcription for UPR chaperones.  ATF4 also induces the gene 
transcription of C/EBP-homology protein (CHOP).  CHOP is a transcription factor that 
induces promoter activation of apoptotic genes.  GCN2, PKR, and HRI are additional 
kinases shown to phosphorylate eIF2α under different stress conditions. 
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ATF6 makes up the second arm of the UPR.  ATF6 is a transcription factor that is 
originally synthesized as an ER-transmembrane protein.  The accumulation of unfolded proteins 
relieves BiP repression of ATF6 and triggers the cleavage of ATF6 from the ER luminal domain 
where it then migrates to the Golgi for further cleavage by additional proteases (Fig. 1.4) (143-
145).  After cleavage by proteases in the Golgi, the N-terminus of ATF6 travels to the nucleus 
and activates gene transcription of target UPR genes.  Interestingly, gene expression analysis of 
ATF6 knockout in mouse embryonic fibroblasts (MEFs) shows loss of ATF6 does not inhibit the 
induction of downstream UPR genes in response to tunicamycin treatment, suggesting a 
redundancy in the UPR pathways (138).  In addition, overexpression of ATF6 in hepatocytes 
does not stimulate hepatic FGF21 gene transcription, concluding that ATF6 does not play a role 
in stress induced FGF21 expression in the liver (131).   
Finally PERK, an ER-resident transmemebrane kinase and the final arm of the UPR, also 
becomes active when ER stress is induced.  Like the previous mechanisms for IRE1α activation, 
BiP de-repression of PERK allows for PERK’s N-terminal ER luminal domain to oligomerize 
(146).  Oligomerization results in the trans-autophosphorylation of PERK’s C-terminal 
cytoplasmic kinase domain and sequential activation of downstream UPR signaling pathways.  
For example, PERK phosphorylates eukaryotic initiation factor 2 alpha (eIF2α) (Fig. 1.4) (147).  
Phosphorylation of eIF2a represses general cap-dependent protein translation while 
simultaneously increasing the translation of specific ER stress chaperones through mRNA cap-
independent mechanisms (148).  In general, unfolded proteins increase the activity of the 
PERK/eIF2α axis such that phosphorylation of eIF2α alleviates ER stress by repressing global 
protein translation, decreasing the flux of newly synthesized proteins into the ER lumen, and 
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increasing the expression of select molecular ER chaperones for the removal and degradation of 
unfolded proteins by ER-associated degradation (ERAD). 
Activating transcription factor 4 (ATF4) is a transcription factor whose protein 
translation is increased after phosphorylation of eIF2α (Fig. 1.4) (148-151).  ATF4 is a basic 
leucine zipper (bZIP) transcription factor that binds, either a homodimer with itself or a 
heterodimer with other bZIP transcription factors, to amino acid response elements (AARE) on 
target gene promoters to induce gene transcription (152-155).  In the liver, ATF4 binds to two 
conserved AAREs located on the FGF21 promoter to stimulate FGF21 gene transcription during 
both nutritional stress (e.g. amino acid deprivation, obesogenic diet) and chemically induced 
stress (e.g. thapsigargin, tunicamycin) (Fig. 1.3) (131,156-162).   
FGF21 expression is induced by multiple arms of the UPR pathway suggesting FGF21 
plays a protective role during a variety of ER stress conditions (139,162-164).  For example, 
selective amino acid deprivation and protein deficient diets increase hepatic FGF21 mRNA 
abundance and circulating FGF21 protein expression (164-167).  The induction of FGF21 during 
methionine, choline, and histidine amino acid deprivation results in weight loss and resistance to 
hepatic steatosis (165,167).  The mechanisms by which amino acid deprivation increases FGF21 
expression is dependent on uncharged tRNA activation of general control nonderepressible 2 
(GCN2), a kinase that phosphorylates eIF2α in response to ER stress (Fig. 1.4) (168).  
Phosphorylation of eIF2α by GCN2 results in increased ATF4 protein translation, enhanced 
binding of ATF4 to AAREs on the FGF21 promoter, and increased FGF21 gene transcription 
(166,167,169).  Notably, the stimulation of hepatic FGF21 gene expression by amino acid 
deficient diets is PPARα- and FXR-independent (165).  Meanwhile metformin, an oral diabetic 
medication used to control blood sugar, induces PERK activity to phosphorylate eIF2α, increase 
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ATF4 protein expression, and stimulate FGF21 gene transcription in primary hepatocytes (160).  
A recent study by Phillipson-Weiner, et al. (2016) showed that loss of GCN2 resulted in amino 
acid deprivation reassigning PERK as the primary kinase for eIF2α when GCN2 was unavailable 
(170).  Like the redundancy previously mentioned for ATF6, these results suggest the UPR may 
mediate eIF2α phosphorylation through either GCN2 or PERK under the same stimulatory 
conditions.  
Phosphorylation of eIF2α is not limited to PERK or GCN2 kinase phosphorylation.  Two 
additional kinases, protein kinase RNA-activated (PKR) and heme-regulated inhibitory kinase 
(HRI), also phosphorylate eIF2α (Fig. 1.4) (171).  PKR activity is induced when double stranded 
RNAs, with a minimum of 33 bp, bind to its dsRNA-binding domain (172,173).  Due to the strict 
requirement of dsRNA activation, PKR activity in the liver is often correlated with viral 
infections such as hepatitis C (174-177).   It is no surprise then that hepatitis C infection 
increases FGF21 mRNA abundance in the liver, presumably through PKR-mediated 
phosphorylation of eIF2α and enhanced transactivation of ATF4 to the FGF21 promoter (178).  
Meanwhile, kinase activity of HRI is increased during times of acute heme-deficient states, 
leading to the phosphorylation of eIF2α and downstream stimulation of ATF4 protein translation 
(Fig. 1.4) (179).  Interestingly, HRI activation is enhanced during high-fat feeding in mice and 
stimulates the eIF2α/ATF4/FGF21 axis in the liver (180).  Together, the above findings present 
eIF2α as a global mediator of hepatic stress pathways (viral (PKR), amino acid deficiency 
(GCN2), heme deficiency (HRI), and unfolded proteins (PERK)) for the translation and 
transactivation of the common transcription factor, ATF4, to induce FGF21 gene transcription in 
the liver.    
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Glucagon and Insulin 
PPARα only partially mediates the stimulatory effect of starvation and a ketogenic diet 
on FGF21 gene expression, suggesting that additional PPARα-independent mechanisms regulate 
FGF21 gene transcription during these dietary conditions.  One such factor that is increased 
during both starvation and HF-LC diets is the pancreatic hormone, glucagon (181-183).  
Hyperglycemia induces the release of glucagon from pancreatic α-cells into blood circulation 
(184-187).  Glucagon signals in the liver to increase factors (e.g. PPARα) involved in 
gluconeogenesis, (e.g. PEPCK) to suppress TG synthesis (182,188,189).   
Glucagon receptor knockout mice are unable to induce FGF21 mRNA abundance in the 
liver during starvation (190).  Additionally, chronic activation of the glucagon receptor increases 
hepatic FGF21 mRNA abundance, circulating FGF21 protein concentration, and weight loss 
(193).  In agreement to these findings, subcutaneous administration of glucagon increases hepatic 
FGF21 mRNA abundance and plasma FGF21 concentrations in mice and humans (190-192) and 
in vitro experiments show glucagon treatment in primary hepatocytes increases FGF21 protein 
secretion (194).  Interestingly, the increase in glucagon stimulated FGF21 protein secretion in 
primary hepatocytes is associated with a transient decrease in FGF21 mRNA abundance.  This 
results suggests that glucagon acts at a translational/posttranslational step to increase hepatic 
FGF21 secretion but does not signal transcriptionally to mediate FGF21 mRNA abundance.  The 
inability of glucagon to induce FGF21 mRNA abundance in hepatocyte cultures (194) contrasts 
with the results of glucagon receptor ablation studies (190,193) demonstrating that the 
starvation-induced increase in FGF21 mRNA abundance is mediated, at least in part, by 
glucagon receptor activation.  One possible explanation for the discrepancy between these 
findings is that glucagon stimulation of FGF21 mRNA abundance requires the presence of 
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another hormone or signaling factor to enhance its transcriptional regulation on FGF21 gene 
transcription.   
Insulin is a hormone secreted from pancreatic β-cells during the fed state and acts upon 
the liver to induce pathways involved in lipogenesis, glycogen synthesis, and energy storage 
(195-198).  Results of studies with mice containing defects in the insulin-signaling pathway 
indicate that insulin is one such factor that potentiates the ability of glucagon to increase FGF21 
mRNA abundance.  Dong et al. (2008) showed that liver-specific ablation of insulin receptor 
substrate 1 and insulin receptor substrate 2 decreased hepatic FGF21 mRNA abundance during 
both the fed and starved state (199).  In addition, Haeusler et al. (2010) have reported that 
streptozotocin-induced diabetes suppressed the stimulatory effect of starvation on hepatic FGF21 
mRNA abundance (200).  In agreement with these loss-of-function studies, insulin infusion 
increases serum FGF21 concentrations in humans (201) and insulin treatment increases both 
FGF21 mRNA abundance and FGF21 protein secretion in primary hepatocytes (194).  Although 
insulin is generally regarded as a hormone signaling the fed state, these observations suggest that 
basal insulin levels play a role in mediating the increase in FGF21 mRNA abundance during the 
starved state as well.   
Most strikingly, glucagon and insulin act cooperatively to increase FGF21 mRNA 
abundance and secretion both in vitro and in vivo (194,202).  Although glucagon opposes insulin 
regulation of a wide variety of metabolic processes, there are multiple scenarios in which 
glucagon enhances insulin actions (203-207).  For example, infusion of glucagon and insulin into 
partially hepatoectomized eviscerated rats synergistically stimulates hepatic DNA synthesis 
(203).  In addition to DNA synthesis, treatment of cultured primary hepatocytes with glucagon or 
glucagon analogs in the presence of insulin robustly induces nuclei proliferation when compared 
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hormone treatment alone (206).  This increase in nuclei proliferation is blocked with the addition 
of H89, suggesting glucagon requires downstream signaling kinase, protein kinase A (PKA), to 
potentiate insulin signaling.  Glucagon also enhances insulin signaling by increasing the activity 
of the insulin tyrosine receptor kinase (205,208).  Glucagon and insulin cooperatively increase 
the insulin tyrosine receptor kinase activity, which leads to the phosphorylation of select 
downstream targets.  This selectivity suggests glucagon may potentiate the ability of insulin to 
active unique, downstream pathways while simultaneously repressing others.  At the present 
time, the mechanisms mediating the synergistic interaction between insulin and glucagon are not 
known. 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
	
OBJECTIVE 
 
Characterize the molecular pathways mediating the ability of starvation and a HF-LC, 
ketogenic diet to stimulate FGF21 mRNA abundance in primary hepatocytes.  
PPARα and FXR only partially mediate the stimulatory effect of starvation and ketogenic 
diet on hepatic FGF21 gene expression, suggesting additional PPARα- and FXR-independent 
mechanisms stimulate FGF21 gene transcription during these dietary conditions.  During 
starvation and HF-LC, ketogenic diets, the portal vein exhibits a high glucagon to insulin ratio.  
Treatment with glucagon and insulin concentrations, similar to that observed during starvation, 
induces FGF21 mRNA abundance in primary hepatocytes.  Additionally, infusion of a high 
glucagon to insulin hormone concentration increases the production and secretion of splanchnic 
FGF21 in humans.  The mechanisms by which glucagon and insulin work cooperatively to 
selectively increase hepatic FGF21 expression and secretion is currently unknown.  Obese and 
T2D humans and mice also exhibit increased bile acid (e.g. CDCA) synthesis and circulating 
FGF21 protein expression.  The objective of this study is to determine the molecular pathways 
mediating the ability of glucagon plus insulin and CDCA to stimulate FGF21 gene transcription 
in primary hepatocytes.  Understanding the fundamental mechanisms by which glucagon plus 
insulin and CDCA signal to induce FGF21 gene transcription will provided in depth knowledge 
on the endogenous regulation of FGF21 expression and also identify additional targets for drug 
development to treat metabolic syndrome. 
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ABSTRACT 
 
 
Previous studies have shown that glucagon cooperatively interacts with insulin to stimulate 
hepatic fibroblast growth factor 21 (FGF21) gene expression.  Here, we investigated the 
mechanisms by which glucagon plus insulin increases FGF21 gene transcription in primary 
hepatocyte cultures.  Transfection analyses demonstrated that glucagon plus insulin induction of 
FGF21 gene transcription was conferred by two activating transcription factor 4 (ATF4) binding 
sites in the FGF21 gene.  Glucagon plus insulin stimulated a 5-fold increase in ATF4 protein 
abundance, and treatment using glucagon plus insulin increased ATF4 binding activity to both 
ATF4 binding sites on the FGF21 promoter.  Knockdown of ATF4 protein expression 
suppressed the ability of glucagon plus insulin to increase FGF21 expression.  In primary rat 
hepatocytes, treatment with a glucagon analog and a protein kinase A (PKA)-selective agonist 
mimicked the ability of glucagon to stimulate ATF4 and FGF21 expression in the presence of 
insulin.  Inhibition of PKA, PI3K, Akt, and mammalian target of rapamycin complex 1 
(mTORC1) suppressed the ability of glucagon plus insulin to stimulate ATF4 and FGF21 
expression.  Additional analyses demonstrated that chenodeoxycholic acid (CDCA) induced a 6-
fold increase in ATF4 expression and primary hepatocytes treated with CDCA increased ATF4 
binding activity to both ATF4 binding sites on the FGF21 promoter.  Knockdown of ATF4 
expression suppressed the ability of CDCA to increase FGF21 gene expression.  CDCA 
increased the phosphorylation of eukaryotic initiation factor 2α (eIF2α), and inhibition of eIF2α 
signaling activity suppressed CDCA regulation of ATF4 and FGF21 expression.  These results 
demonstrate that glucagon plus insulin increases FGF21 transcription by stimulating ATF4 
expression and that activation of the glucagon mediated cAMP/PKA pathway and the insulin 
mediated PI3K/Akt/mTORC1 pathway regulates the effect of glucagon plus insulin on ATF4 
expression.  These results also demonstrate that CDCA regulation of FGF21 transcription is 
mediated at least partially by an eIF2α-dependent increase in ATF4 expression. 
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INTRODUCTION 
 
FGF21 is an atypical member of the fibroblast growth factor family that lacks the ability 
to bind to heparin sulfate proteoglycans allowing it to escape the extracellular matrix and 
function in an endocrine manner (1-3).  Studies investigating the biological action of FGF21 
have shown that starvation and other nutritional stresses (e.g. dietary protein restriction, 
consumption of a high-fat, low-carbohydrate ketogenic diet, and consumption of a high-fat 
obesogenic diet) stimulate an increase in the expression and secretion of FGF21 by the liver, the 
predominant site of FGF21 production in the body (4-10).  FGF21 signals through FGF receptor 
1c (FGFR1c) linked to the co-receptor, β-Klotho, to increase food intake, energy expenditure, 
gluconeogenesis, and insulin sensitivity and inhibit growth and female fertility in response to 
nutritional stress (1-6,11) 
Several signaling pathways have been identified that mediate the effects of nutritional 
stress on FGF21 expression.  One such pathway involves the activation of the nuclear receptor, 
peroxisome proliferator-activated receptor-α (PPARα).  Natural (i.e. non-esterified unsaturated 
fatty acids) and synthetic ligands of PPARα induce hepatic FGF21 gene expression (7,8,12,13).  
A PPARα response element (PPRE) has been identified in the 5’-flanking region of the murine 
and human FGF21 genes (8,13).  Ablation of the PPARα gene suppresses the ability of starvation 
and ketogenic diet consumption to increase hepatic FGF21 mRNA abundance and serum FGF21 
concentrations (7,8). 
Another pathway mediating the nutritional regulation of FGF21 expression is activated 
by the glucagon receptor.  This has been deduced from studies in mice showing that ablation of 
the glucagon receptor suppresses the ability of starvation to increase hepatic FGF21 mRNA 
abundance and serum FGF21 concentration (14).  In examining the mechanism by which 
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glucagon increases FGF21 production, we have shown that incubating rat and human hepatocyte 
cultures with glucagon causes a 3-fold increase in FGF21 secretion into the culture medium (15).  
Interestingly, the glucagon-induced increase in FGF21 secretion in hepatocytes is associated with 
a transient decrease in FGF21 mRNA abundance suggesting that glucagon acts at a 
translational/posttranslational step to increase hepatic FGF21 secretion. 
The inability of glucagon to induce FGF21 mRNA abundance in hepatocyte cultures (15) 
contrasts with the results of glucagon receptor ablation studies (14) demonstrating that the 
starvation-induced increase in FGF21 mRNA abundance is mediated at least partially by 
glucagon receptor activation.  One possible explanation for the discrepant findings is that 
glucagon stimulation of FGF21 mRNA abundance requires the presence of another hormone or 
signaling factor.  Results of studies with intact mice containing defects in the insulin-signaling 
pathway suggest that insulin is one such factor that potentiates the ability of glucagon to increase 
FGF21 mRNA abundance.  Dong et al. (16) have shown that liver-specific ablation of insulin 
receptor substrate-1 (IRS-1) and insulin receptor substrate-2 (IRS-2) causes a decrease in hepatic 
FGF21 mRNA abundance during both the fed state and the starved state.  In addition, Haeusler et 
al. (17) have reported that streptozotocin-induced diabetes suppresses the stimulatory effect of 
starvation on hepatic FGF21 mRNA abundance.  Although insulin is generally regarded as a 
hormone signaling the fed state, these observations suggest that basal insulin levels play a role in 
mediating the increase in FGF21 mRNA abundance during the starved state.   
In support of this possibility, we have shown that insulin potentiates the ability of 
glucagon to stimulate FGF21 mRNA abundance in primary rat hepatocyte cultures (15).  
Treatment with insulin alone stimulates a 3.5-fold increase in FGF21 mRNA abundance and the 
addition of glucagon in the presence of insulin causes a further 2.5-fold elevation in FGF21 
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mRNA abundance.  This cooperative interaction between glucagon and insulin in the regulation 
of FGF21 mRNA abundance is associated with a substantially greater induction of FGF21 
secretion (i.e. 28-fold) relative to that by insulin or glucagon alone.  The insulin concentration 
that is required to unmask glucagon regulation of FGF21 mRNA abundance is similar to that 
observed in the portal circulation during the starved state (15).  We have postulated that insulin 
maintains a basal level of hepatic FGF21 mRNA abundance during the carbohydrate-fed state 
and synergistically interacts with elevated glucagon levels during the starved state to stimulate a 
further increase in FGF21 mRNA abundance.  The mechanism by which glucagon and insulin 
increase FGF21 mRNA abundance is presently not known.  
In addition to PPARα, glucagon, and insulin, the farnesoid X receptor (FXR) plays a role 
in the regulation of hepatic FGF21 production.  We have shown that natural (i.e. bile acids) and 
synthetic activating ligands (i.e. GW4064) of FXR stimulate an increase in hepatic FGF21 
mRNA abundance and secretion in rodent and human hepatocyte cultures (12).  The effect of 
GW4064 on FGF21 gene transcription is mediated, at least in part, by a conserved FXR response 
element (FXRE) that binds heterodimers comprised of FXR and RXR.  Ablation of the FXR 
gene suppresses the ability of ketogenic diet consumption to induce hepatic FGF21 mRNA 
abundance and serum FGF21 concentration. 
In our studies analyzing the bile acid regulation of FGF21 expression, chenodeoxycholic 
acid (CDCA) was substantially more effective in inducing FGF21 gene expression in 
hepatocytes than a selective FXR activating ligand (i.e. GW4064) that bound to FXR with a 
>100-fold higher affinity than that of CDCA (12).  Incubating rodent and human hepatocyte 
cultures with an optimal concentration of CDCA (100 µM) stimulated a 25-fold increase in 
FGF21 mRNA abundance, whereas incubating hepatocytes with an optimal concentration of 
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GW4064 (3 µM) stimulated a 3.2-fold increase in FGF21 mRNA abundance.  These 
observations suggested that another mechanism(s) besides ligand activation of FXR is involved 
in mediating the stimulatory effect of bile acids on FGF21 gene transcription.  This nature of this 
mechanism has not yet been defined. 
The objective of the present study is to characterize the mechanisms by which glucagon 
plus insulin and CDCA increase hepatic FGF21 gene expression.  We show that glucagon plus 
insulin and CDCA increase the expression of the stress-associated transcription factor, activating 
transcription factor 4 (ATF4), and that this protein plays a key role in mediating the stimulatory 
effect of these signaling factors on FGF21 gene transcription.  We have also characterized the 
proximal signaling pathways mediating the effects of glucagon plus insulin and CDCA on ATF4 
and FGF21 expression. 
 
 
EXPERIMENTAL PROCEDURES 
 
Cell Culture- Primary hepatocytes were isolated from 24 h starved male Sprague Dawley rats 
(approximately 175-200 g) as described by Stabile et al. (18).  Cells were plated on 35-mm or 
60-mm collagen-coated dishes (1.4 x 105 cells/cm2) containing Waymouth’s medium MD752/1 
supplemented with 20 mM HEPES, pH 7.4, 0.5 mM serine, 0.5 mM alanine, 100 mg/ml 
penicillin, 100 mg/ml streptomycin, 50 mg/ml gentamicin, and 5% newborn calf serum.  At 4 h 
of incubation, the medium was replaced with one of the same composition lacking newborn calf 
serum.  A Matrigel overlay (0.3 mg/ml) and insulin (50 nM) were added at this time.  At 24 h of 
incubation, the cells were washed in serum-free Medium 199 lacking insulin, and the incubation 
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was continued in serum-free Medium 199.  At 48 h of incubation, the medium was replaced with 
one of the same composition containing the treatments indicated in the figure legends.  
Hepatocyte cultures were maintained in a humidified chamber at 37°C in 5% CO2 and 95% air.  
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes Health and was approved by the 
Institutional Animal Care and Use Committee of West Virginia University (Protocol Approval 
Number: 15-0904). 
Chenodeoxycholic acid, dibutyryl cAMP, and Akti-1/2 were obtained from Sigma-
Aldrich.  Rapamycin and LY294002 were purchased from LC Laboratories.  H89 and ISRIB 
were obtained from Cayman.  Bovine insulin was a gift from Lilly.  N6- Benzoyladenosine- 3', 
5'- cyclic monophosphate (Biolog) and 8-(4-chlorophenylthio)-2'-O-methyladenosine- 3', 5'-
cyclic monophosphate (R&D Systems) were obtained from the indicated sources. 
 
Transient Transfection- The construction of reporter plasmids containing fragments of the rat 
FGF21 promoter/regulatory region linked to the luciferase gene has been previously described 
(12).  Site-directed mutations were introduced into the -1316 to +68 bp FGF21 reporter plasmid 
using the Agilent QuikChange II XL site-directed mutagenesis kit.  Hepatocytes were plated on 
35-mm dishes and transfected with 1 µg of the -2940 to +68 FGF21 reporter plasmid or an 
equimolar amount of another reporter plasmid using Lipofectin reagent (Invitrogen).  At 18 h of 
incubation, the transfection medium was replaced with fresh medium and a Matrigel overlay (0.3 
mg/ml) was added.  At 48 h of incubation, the medium was replaced with fresh medium with or 
without glucagon plus insulin.  At 72 h incubation, cells were harvested and cell extracts were 
prepared in 1x Cell Culture Lysis Buffer (Promega).  Cell extracts were centrifuged at 12,000 x g 
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for 2 min and the supernatants were assayed for protein concentration and luciferase activity.  
Luciferase assay reagent was obtained from Promega.  
 
siRNA Knockdown Experiments- Primary hepatocytes were plated on 35-mm dishes and 
transfected with 30 pmols of siRNA targeting ATF4 (Silencer Select siRNA IDs: s135172 and 
s135173, Ambion), 30 pmols of siRNA targeting ChREBP (Silencer Select siRNA ID: s139670) 
or 30 pmols of negative control #1 siRNA (Ambion) using Lipofectamine RNAiMAX reagent 
(Invitrogen).  At 18 h of incubation, the transfection medium was replaced with Medium 199 and 
a Matrigel overlay (0.3 mg/ml) was added.  The medium was replaced with fresh medium at 48 h 
and 66 h of incubation.   After the medium change at 66 h of incubation, cells were treated with 
or without CDCA for 2 h or glucagon plus insulin for 12 h.  Cells were then harvested, cell 
extracts prepared, and total RNA isolated. 
 
Western Analysis- Total cell extracts were prepared from hepatocytes as described by 
Hansmannel et al. (19) except that the lysis buffer contained 25 mM Tris-HCl, pH 7.6, 150 mM 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and a mixture of protease inhibitors and 
phosphatase inhibitors (Halt, Thermo Scientific).  Equal amounts of denatured protein were 
subjected to electrophoresis in SDS-polyacrylamide gels and then transferred to polyvinylidene 
difluoride membranes (Immobilon-FL, Millipore) using an electroblotting apparatus (Bio-Rad).  
The blots were blocked in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1% Tween) 
containing 5% nonfat dry milk for 1 h at room temperature and then incubated with primary 
antibody diluted 1:1000 in TBST containing 5% bovine serum albumin.  After incubation with 
primary antibody for 12 h at 4°C, the blots were washed in TBST.  Next, the blots were 
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incubated with secondary antibody conjugated to horseradish peroxidase (Jackson 
ImmunoResearch) diluted 1:5000 in TBST, for 1 h at room temperature.  After washing with 
TBST, antibody/protein complexes on blots were detected using enhanced chemiluminescence 
(Amersham Biosciences).  Fluorescence on the blots was visualized using a Typhoon 9410 
imager and signals were quantified using ImageQuant software.  Antibodies against ATF4, 
phosphorylated Akt (Ser473), phosphorylated eIF2α (Ser51), phosphorylated ribosomal protein S6 
(Ser235/236), total Akt, total eIF2α, total ribosomal protein S6, and β-tubulin were obtained from 
Cell Signaling Technology. 
 
Isolation of RNA and Quantitation of mRNA levels- Total RNA was extracted from cell cultures 
by the guanidinium thiocyanate/phenol/chloroform method (20).  The abundance of mRNA 
encoding FGF21, ATF4, sterol regulatory element-binding protein-1c (SREBP-1c), and 
phosphoenolpyruvate carboxykinase (PEPCK) was measured by quantitative real-time PCR 
analysis using the QIAGEN Quantitect SYBR green RT-PCR system.  Samples of DNase I-
treated RNA (100 ng) were analyzed in triplicate according to the manufacturer’s instructions.  
PCR was performed in ninety-six well plates using a Bio-Rad iCycler iQ.  The relative amount 
of mRNA was calculated using the comparative Ct method.  Rat cyclophilin and glucouronidase 
beta were used as reference genes.  Amplification of specific transcripts was confirmed by 
analyzing the melting curve profile performed at the end of each run and by determining the size 
of the PCR products using agarose electrophoresis and ethidium bromide staining.  The 
sequences of the primer sets can be obtained from the corresponding author upon request. 
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Preparation of Nuclear Extracts- All of the procedures were carried out on ice. To prevent 
proteolysis, a mixture of protease inhibitors (HaltTM; ThermoFisher Scientific) was included in 
all of the buffers. The nuclear extracts were prepared from primary rat hepatocytes by a 
modification of the method described by Dignam et al. (21). Briefly, rat hepatocytes from eight 
100-mm plates were pooled and centrifuged and centrifuged at 250 x g for 5mins at 4°C. The 
resulting cell pellet was washed with PBS and centrifuged a second time at 1000 x g for 5 min. 
The resulting cell pellet was incubated in buffer 1 (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2, 1 mM EDTA, 1 mM dithiothreitol) for 10 min on ice then homogenized using 25 strokes 
in a type A Dounce homogenizer. The nuclear pellet was centrifuged at 1100 x g for 10 min, 
supernatant aspirated, and centrifuged again at 1100 x g for 10 min. The nuclear pellet was 
resuspended in Buffer 2 (20 mM Hepes, pH 7.9, 420 mM NaCl, 25% (v/v) glycerol, 1.5 mM 
MgCl2, 1 mM EDTA, 1 mM dithiothreitol).  The resuspension was homogenized using 15 
strokes in a type B Dounce homogenizer, rotated for 30 min at 4°C, and centrifuged at 16000 x g 
for 30 min. The resulting supernatant was designated as the nuclear extract fraction. 
 
Gel Mobility Shift Analysis- Double-stranded olgionucleotides were prepared by combining 
equal amounts of the complementary single-stranded DNA in a solution containing 10 mM Tris, 
pH 8.0 and 50 mM NaCl follow by heating to 95°C for 2 min and then cooling to room 
temperature. The annealed olgionucleotides were labeled by filling in overhanging 5’ ends using 
the Klenow fragment of Escherichia coli DNA polymerase in the presence of [α-32P] dGTP. The 
binding reactions were carried out in 30 µL of 15 mM Hepes, pH 7.9, 150 mM NaCl, 0.5 mM 
MgCl2, 0.35 mM EDTA, 0.35 mM dithiothreitol, 15% glycerol (v/v), 0.2 mg/mL bovine serum 
albumin, 0.25% Triton X-100 (v/v), and 0.5 µg poly d(I-C). 20 µg of nuclear extract and reaction 
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buffer were incubated on ice for 20 min prior to addition of 50,000 cpm of labeled DNA and 
incubation at room temperature for 20 min. DNA and DNA-protein complexes were resolved on 
5% nondenaturing polyacrylamide gels at 4°C in 1xTris-Glycine (0.5 M Tris, pH 8.8, 4 M 
Glycine). Following electrophoresis, the gels were dried and subjected to phosphor 
autoradiography. The synthetic oligonucleotides that were used as probes in gel mobility shift 
assays are listed in Fig. 2A. 
 
Statistical Methods- Data were subjected to analysis of variance, and statistical comparisons 
were made with the Student’s t-test. 
 
 
RESULTS 
 
Identification of Cis-acting Sequences That Mediate the Stimulatory Effect of Glucagon Plus 
Insulin on FGF21 Gene Transcription.   
To identify cis-acting sequences mediating the stimulatory effect of glucagon plus insulin 
on FGF21 gene expression, transient transfection experiments were performed in primary rat 
hepatocyte cultures using reporter constructs containing 5’-deletions of the rat FGF21 promoter 
linked to the luciferase gene.  In cells transfected with the longest FGF21 fragment (-2940 to +68 
bp), treatment with glucagon plus insulin stimulated a 10.8-fold increase in luciferase activity 
(Fig. 2.1).  5’-Deletion of FGF21 sequences to -1656 bp and -1316 bp had no effect on glucagon 
plus insulin responsiveness, whereas 5’-deletion of sequences to -1241 bp caused a 55% decrease 
in glucagon plus insulin responsiveness.  Further 5’-deletion of FGF21 sequences to -1164 bp 
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had no effect on remaining glucagon plus insulin responsiveness, whereas deletion of sequences 
from -1164 to -103 caused a 46% decrease in glucagon plus insulin responsiveness.  These 
results indicate that there are two regions (-1316 to -1241 bp and -1164 to -103 bp) that confer 
the stimulatory effect glucagon plus insulin on FGF21 gene transcription.  Due to the small effect 
of insulin alone on FGF21 gene expression and the variability of the transient transfection assay, 
we were unable to identify FGF21 sequences that conferred regulation of transcription by insulin 
alone.  Insulin treatment in the absence of glucagon did not stimulate a significant increase in the 
activity of any of the FGF21 reporter constructs (Fig. 2.2).   
FGF21 sequences between -1316 to -1241 bp and between -1164 to -103 bp each contain 
a previously characterized sequence element that binds the stress-associated transcription factor, 
activating transcription factor 4 (ATF4) (22).  Both of these elements play a role in mediating the 
stimulatory effect of essential amino acid deficiency on FGF21 gene transcription.  They are 
designated as amino acid response element (AARE) 1 and AARE2 (Fig. 2.3A).  To determine 
whether AARE1 and AARE2 mediate the stimulatory effect of glucagon plus insulin on FGF21 
gene transcription, FGF21 reporter constructs were developed that contained site-specific 
mutations that abolished ATF4 binding to AARE1, AARE2 or both AARE1 and AARE2 in 
context of the -1316 to +68 bp FGF21 reporter construct.  Mutation of the upstream AARE1 (-
1282 to -1274 bp) or the downstream AARE2 (-140 to -132 bp) caused a 54-56% decrease in 
glucagon plus insulin responsiveness (Fig. 2.3B).  Mutation of both AARE1 and AARE2 caused 
an 87% decrease in glucagon plus insulin responsiveness.  In contrast to the effect of mutation of 
AARE1 and AARE2 on glucagon plus insulin regulation of FGF21 promoter activity, mutations 
that abolished FXR and PPARa binding to the FGF21 FXRE/PPRE (–1222 to -1203 bp) and 
carbohydrate response element binding protein binding to the FGF21 carbohydrate response 
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element (ChoRE, –72 to -56 bp) had no effect on the ability glucagon plus insulin to stimulate 
FGF21 promoter activity (Fig. 2.3B).  These data indicate that glucagon and insulin act 
selectively through both of the AAREs in the FGF21 5-flanking DNA to induce FGF21 gene 
transcription. 
 
Role of ATF4 in Mediating the Stimulatory Effect of Glucagon Plus Insulin on FGF21 Gene 
Transcription.   
Previous studies have shown that ATF4 binds to AARE1 and AARE2 in hepatocytes and 
that expression of exogenous ATF4 in hepatocytes induces FGF21 gene transcription (22).  
These observations plus the results of the present study demonstrating that glucagon and insulin 
signal through AARE1 and AARE2 to induce FGF21 gene transcription led us to investigate 
whether glucagon and insulin modulated ATF4 expression in hepatocyte cultures.  Incubating 
hepatocytes with insulin or glucagon alone for 12 h had no effect on ATF4 protein concentration 
or ATF4 mRNA abundance, whereas incubating hepatocytes with glucagon plus insulin 
stimulated a 5.3-fold increase in ATF4 protein concentration and 1.6-fold increase in ATF4 
mRNA abundance (Fig. 2.4A).  This cooperative interaction between glucagon and insulin in the 
regulation of ATF4 expression mirrored the regulation of FGF21 mRNA abundance by these 
hormones.  In contrast, glucagon antagonized the ability of insulin to induce the expression of 
the lipogenic transcription factor, SREBP-1c (Fig. 2.4A).  These findings demonstrate that 
glucagon and insulin cooperatively interact to increase ATF4 expression and that this effect is 
selective for ATF4 and its downstream targets.  
Gel mobility shift assays were performed to determine whether the stimulatory effect of 
glucagon plus insulin on ATF4 expression was associated with an elevation in the binding of 
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ATF4 to AARE1 and AARE2.  Nuclear extracts were prepared from hepatocytes incubated with 
or without glucagon plus insulin for 12 h.  Incubation of nuclear extracts with 32P-labeled DNA 
probes containing the AARE1 or AARE2 resulted in the formation of multiple protein-DNA 
complexes (Fig. 2.4B).  Competition analyses indicated that the binding of several of these 
DNA-protein complexes was specific.  The abundance of these specific protein-DNA complexes 
was increased in nuclear extracts from hepatocytes treated with glucagon plus insulin.  
Preincubation of nuclear extracts with ATF4 antibody partially disrupted the formation of these 
protein-DNA complexes and caused the formation of new supershifted complexes.  The 
abundance of these supershifted complexes was elevated in nuclear extracts from hepatocytes 
treated with glucagon plus insulin.  These observations indicate that glucagon plus insulin 
increases the ATF4 binding to AARE1 and AARE2. 
To further establish a role of ATF4 in mediating the stimulatory effect of glucagon plus 
insulin on FGF21 expression, we investigated whether knockdown of ATF4 expression 
modulated the ability of glucagon plus insulin to increase FGF21 expression.  Primary rat 
hepatocytes were transfected with siRNAs targeting ATF4 (ATF4 siRNA 1 and ATF4 siRNA 2) 
or a non-targeting control siRNA and were treated with or without glucagon plus insulin.  
Transfection of hepatocytes with ATF4 siRNA 1 or ATF4 siRNA 2 inhibited both basal ATF4 
protein expression and glucagon plus insulin induction of ATF4 protein expression relative to 
untransfected cells or cells transfected with control siRNA (Fig. 2.5).  These effects on ATF4 
expression were associated with a reduction in basal FGF21 mRNA abundance and the ability of 
glucagon plus insulin to increase FGF21 mRNA abundance.  These results demonstrate that 
glucagon plus insulin regulation of FGF21 gene expression is dependent on ATF4. 
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Role of ChREBP in Mediating the Stimulatory Effect of Glucagon Plus Insulin on FGF21 Gene 
Transcription.   
Previous studies show the carbohydrate response element binding protein (ChREBP) 
increases FGF21 gene transcription by binding to and activating a downstream carbohydrate 
response element (ChoRE) on the FGF21 promoter in primary hepatocytes (23-25). These 
observations led us to ask whether ChREBP may play a passive role in enhancing glucagon plus 
insulin signaling through ATF4 binding at AARE1 and AARE2 to induce FGF21 gene 
transcription in hepatocytes cultures.  Primary rat hepatocytes were transfected with siRNAs 
targeting ChREBP (ChREBP siRNA) or a non-targeting control siRNA and were treated with or 
without glucagon plus insulin.  Transfection of hepatocytes with ChREBP siRNA inhibited the 
mRNA abundance for both ChREBP and downstream transcriptional target of ChREBP, liver 
pyruvate kinase (LPK), relative to cells transfected with control siRNA (Fig. 2.6).  In contrast to 
ATF4 protein knockdown (Fig. 2.5), repression of ChREBP expression was not associated with a 
reduction in basal FGF21 mRNA abundance or did it hinder the ability of glucagon plus insulin 
to increase FGF21 mRNA abundance.  In addition, glucagon plus insulin treatment did not 
induce LPK mRNA expression suggesting ChREBP activity is not enhanced during glucagon 
plus insulin treatment.  These results demonstrate that glucagon plus insulin regulation of FGF21 
gene expression does not require ChREBP and is dependent on ATF4. 
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Downstream Insulin Mediators, PI3K, Akt, and mTORC1, Mediate the Stimulatory Effect of 
Insulin and Glucagon on FGF21 and ATF4 Expression.   
We next investigated the proximal signaling pathways mediating the synergistic effect of 
glucagon and insulin on FGF21 and ATF4 expression.  Insulin activation of the insulin receptor 
stimulates PI3K activity that in turn increases the conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) (26).  Elevated PIP3 levels 
leads to an increase in the phosphorylation and activation of Akt (also known as protein kinase 
B).  We performed studies with specific inhibitors of PI3K (i.e. LY294002) and Akt (i.e. Akti-
1/2) to investigate the role of the PI3K/Akt pathway in mediating the cooperative interaction of 
insulin with glucagon in inducing FGF21 gene expression.  Incubating hepatocytes with 
LY294002 or Akti-1/2 suppressed the ability of glucagon plus insulin to stimulate FGF21 
mRNA abundance and ATF4 protein concentration in a dose-dependent manner (Figs. 2.7A and 
2.7B).  In agreement with previous studies (27), Western analyses showed that insulin increased 
the abundance of the phosphorylated, active form of Akt (Ser473) and that the presence of 
glucagon amplified this effect (Fig. 2.7A).  The ability of LY294002 and Akti-1/2 to suppress the 
stimulatory effect of glucagon plus insulin on FGF21 and ATF4 expression was associated with 
a decrease in phosphorylated Akt (Figs. 2.7A and 2.7B).  Surprisingly, treatment with LY294002 
or Akti-1/2 did not suppress the ability of glucagon plus insulin to stimulate ATF4 mRNA 
abundance (Figs. 2.8A and 2.8B).  These data demonstrate that insulin interacts with glucagon in 
a cooperative manner to stimulate Akt activity and that Akt is required for the stimulatory effect 
of glucagon plus insulin on FGF21 and ATF4 expression. 
The hepatic insulin-signaling pathway bifurcates at a step distal to Akt.  Akt 
phosphorylates FoxO1 leading to inactivation of gluconeogenic enzyme gene transcription 
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(28,29).  Alternatively, Akt phosphorylates tuberous sclerosis complex 2 (TSC2) leading to an 
activation of mammalian target of rapamycin complex 1 (mTORC1) and an increase in lipogenic 
gene expression (29,30).  To evaluate the role mTORC1 in mediating the induction of FGF21 
gene expression by glucagon plus insulin, we conducted experiments employing the specific 
mTORC1 inhibitor, rapamycin.  Incubating hepatocytes with 1 nM rapamycin suppressed the 
ability of glucagon plus insulin to increase FGF21 mRNA abundance and ATF4 protein 
concentration by 65% and 44%, respectively (Fig. 2.7C).  The rapamycin-mediated reduction in 
glucagon plus insulin regulation of FGF21 mRNA abundance and ATF4 protein concentration 
was associated with a decrease in the phosphorylated active form of ribosomal protein S6, an 
effector protein downstream of mTORC1.  In contrast, treatment with rapamycin had no effect 
on the abundance of the phosphorylated, active form of Akt.  Unexpectedly, treatment with 
Rapamycin also did not suppress the ability of glucagon plus insulin to stimulate ATF4 mRNA 
abundance (Fig. 2.8C).  These data suggest that insulin signals through the mTORC1 branch of 
the insulin pathway to potentiate the stimulatory effect of glucagon on FGF21 and ATF4 
expression. 
 
Downstream Glucagon Signaling Mediator PKA, but not EPAC, Mediate the Stimulatory Effect 
of Insulin and Glucagon on FGF21 and ATF4 Expression.   
We next characterized the glucagon-signaling pathway mediating the induction of FGF21 
and ATF4 expression by glucagon plus insulin.  Glucagon regulates hepatic metabolic processes 
by binding to the glucagon receptor, stimulating an increase in adenylyl cyclase activity resulting 
in an elevation in cAMP production (31).  Increased intracellular cAMP levels, in turn, activate 
protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), a guanine 
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nucleotide exchange factor that activates the small GTPase Rap1 (31,32).  To assess the role of 
the cAMP/PKA pathway and the cAMP/EPAC pathway in mediating the stimulatory effect of 
glucagon plus insulin on FGF21 gene expression, we tested the ability of a membrane permeable 
form of cAMP (i.e. dibutyryl cAMP), a PKA-selective agonist [i.e. N6-benzoyladenosine-3′,5′-
cyclic monophosphate (6-Bnz-cAMP)] (33), and a EPAC-selective agonist [i.e. 8-(4-
chlorophenylthio)-2'-O-methyladenosine- 3', 5'-cyclic monophosphate (cpTOME)] (34) to mimic 
the glucagon induction of FGF21 mRNA abundance in the presence of insulin.  In hepatocytes 
incubated in culture medium containing insulin, addition of dibutyryl cAMP or 6-Bnz-cAMP 
stimulated a 10 to 11-fold increase in FGF21 mRNA abundance (Fig. 2.9A).  This increase in 
FGF21 mRNA abundance was similar in magnitude to that observed when glucagon was added 
to the culture medium.  Dibutyryl cAMP and 6-Bnz-cAMP also mimicked the ability of 
glucagon to stimulate ATF4 protein concentration, ATF4 mRNA abundance, Akt Ser473 
phosphorylation, and ribosomal protein S6 Ser235/236 phosphorylation in the presence of insulin 
(Figs. 2.9A and 2.9B).  In contrast, addition of cpTOME to the culture medium had no effect on 
FGF21 mRNA abundance, ATF4 protein concentration, ATF4 mRNA abundance, and Akt Ser473 
phosphorylation in hepatocytes incubated with insulin.  cpTOME treatment was effective in 
stimulating ribosomal protein S6235/236 phosphorylation, suggesting the EPAC activation in the 
presence of insulin induces ribosomal protein S6 phosphorylation via a mechanism that is 
independent of changes in Akt activity.  This observation is concordant with previous work 
showing that EPAC activation of Rap1 stimulates ribosomal protein S6 phosphorylation via a 
PI3K/Akt-independent mechanism (35).  These data suggest that the glucagon signals through 
cAMP and PKA, but not through EPAC, to induce FGF21 and ATF4 expression in the presence 
of insulin. 
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To obtain further evidence that PKA plays a role in mediating the stimulatory effect of 
glucagon and insulin on FGF21 gene expression, experiments were conducted using the PKA-
selective inhibitor, H89 (36).  Incubating hepatocytes with H89 suppressed the ability of 
glucagon plus insulin to induce FGF21 mRNA abundance and ATF4 protein concentration (Fig. 
2.10A).  As a positive control for inhibition of PKA, H89 was effective in suppressing the 
stimulatory effect of glucagon on the abundance of mRNA encoding PEPCK, a PKA target (Fig. 
2.10B) (37).  These results provide support for a role of PKA in mediating the increase FGF21 
gene expression caused by glucagon plus insulin.  
 
CDCA Stimulates FGF21 Gene Expression via an ATF4-dependent Mechanism.   
CDCA induces FGF21 gene expression not only by ligand activation of FXR but also by 
an undefined mechanism that is independent of ligand activation of FXR (12).  Other work has 
shown that elevated levels of hepatic bile acids stimulate the accumulation of aberrant proteins in 
the endoplasmic reticulum (ER) and induce markers of ER stress (i.e. Grp78 and CHOP) (38).  
These observations, in combination with the current findings demonstrating that the stress 
associated protein ATF4 mediates the stimulatory effect of glucagon plus insulin on FGF21 
expression, prompted us to investigate whether ATF4 plays a role in mediating the stimulatory 
effect of CDCA on FGF21 expression.  We first examined whether CDCA modulated hepatic 
ATF4 expression.  Incubating hepatocyte cultures with 100 mM CDCA for 2 h stimulated a 6-
fold increase in ATF4 protein concentration and a 2.7-fold increase in ATF4 mRNA abundance 
(Fig. 2.11A).  Results from gel mobility shift analyses demonstrated that this CDCA-induced 
increase in ATF4 expression was associated with an elevation in ATF4 binding to AARE1 and 
AARE2 (Fig. 2.11B).  The specific binding of proteins to AARE1 and AARE2 was elevated in 
 
	
62 
nuclear extracts from hepatocytes treated with CDCA.  Preincubation of nuclear extracts with 
ATF4 antibody disrupted the formation of these DNA-protein complexes and caused the 
formation of new supershifted complexes.  The abundance of these supershifted complexes were 
elevated in nuclear extracts from hepatocytes treated with CDCA.   
We next investigated whether knockdown of ATF4 expression modulated the ability of 
CDCA to induce FGF21 expression.  Transfection of hepatocytes with ATF4 siRNA 1 or ATF4 
siRNA 2 suppressed the ability of CDCA to increase FGF21 mRNA abundance by 53 to 59% 
relative to cells transfected with control siRNA (Fig. 2.11C).  Diminished CDCA regulation of 
FGF21 expression in cells transfected with ATF4 siRNA 1 and ATF4 siRNA 2 was associated 
with a marked reduction in ATF4 protein expression.  These results indicate that CDCA 
increases ATF4 expression and ATF4 binding to the FGF21 gene and that ATF4 is required for 
CDCA induction of FGF21 gene expression. 
 
Akt and Phosphorylated eIF2α Mediate the Stimulatory Effect of CDCA on FGF21 Gene 
Expression.   
Treatment of hepatocytes with CDCA stimulates Akt activity via mechanisms involving 
the increased production of mitochondrial reactive oxygen species (39) and the increased 
production of phosphatidic acid, a cellular metabolite that promotes Akt phosphorylation (40).  
These observations led us to investigate whether Akt plays a role in mediating the stimulatory 
effect of CDCA on FGF21 and ATF4 expression.  Treatment of hepatocytes with Akti-1/2 
suppressed the ability of CDCA to stimulate FGF21 mRNA abundance but had no effect on the 
ability of CDCA to increase ATF4 protein concentration (Fig. 2.12A).  This finding suggests that 
Akt mediates the stimulatory effect of CDCA on FGF21 expression but not through a mechanism 
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involving changes in ATF4 expression.  The inability of Akt inhibition to suppress the 
stimulatory effect of CDCA on ATF4 expression raised the possibility that another signaling 
pathway besides Akt is involved in mediating CDCA regulation of FGF21 expression.  ER stress 
increases the phosphorylation (Ser51) of eukaryotic translation initiation factor 2α (eIF2α) (41).  
Phosphorylated eIF2α (P-eIF2α) represses global protein translation while selectively increasing 
the translation of ATF4 mRNA (42).  To investigate the role of P-eIF2α in mediating the 
stimulatory effect of CDCA on FGF21 and ATF4 expression, experiments were performed using 
integrated stress response inhibitor B (ISRIB), a cell permeable small molecule that inhibits the 
downstream actions of P-eIF2α without affecting eIF2α phosphorylation state (43).  Treatment of 
hepatocyte cultures with CDCA stimulated a 3.5-fold increase in the abundance of P-eIF2α but 
had no effect on the abundance of total eIF2a (Fig. 2.12B).  Incubating cells with ISRIB 
suppressed the ability of CDCA to increase FGF21 mRNA abundance and ATF4 protein 
concentration by 86% and 55%, respectively.  These results suggest that CDCA signals through 
P-eIF2α to induce FGF21 and ATF4 expression. 
 
 
DISCUSSION 
 
The present study identifies two new signaling pathways controlling FGF21 gene 
transcription.  In the first pathway, glucagon activation of PKA in the presence of insulin 
stimulates the activity of mTORC1, a signaling complex that promotes an increase in the 
expression of the transcription factor ATF4.  Elevated ATF4 expression in turn stimulates 
FGF21 gene transcription (Fig. 2.13).  In the second pathway, CDCA stimulates eIF2α 
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phosphorylation, causing an elevation in ATF4 expression and an increase in FGF21 gene 
transcription.  To our knowledge, this is the first report demonstrating a role for ATF4 in 
mediating the effects of glucagon, insulin, and bile acids on hepatic gene expression.  An 
elevation in ATF4 expression has been shown to mediate the stimulatory effect of essential 
amino acid deficiency on FGF21 gene transcription (22).  This finding together with the results 
of the present study indicate that ATF4 is a distal regulatory factor that integrates a wide range of 
nutritional and hormonal signals controlling FGF21 gene transcription. 
Previous studies have shown that ectopic activation of mTORC1 via knockdown of TSC1 
causes an increase in FGF21 gene expression (44).  Expression of exogenous ATF4 or a 
constitutively active form of Akt also induces FGF21 gene expression (22,45).  These findings 
provide support for our model that an elevation in mTORC1 signaling activity and ATF4 
expression is involved in mediating that stimulatory effect of glucagon plus insulin on FGF21 
gene transcription.   
Our results show that inhibition of PI3K, Akt, and mTORC1 repressed glucagon plus 
insulin stimulation of FGF21 mRNA abundance and ATF4 protein expression, but did not 
repress the ability of glucagon plus insulin to increase ATF4 mRNA abundance (Figs. 2.7 and 
2.8).  These results suggest that the PI3K/Akt/mTORC insulin signaling axis plays a 
posttranscriptional role in mediating glucagon plus insulin induction of ATF4 expression.  
Previous studies have shown short term fasting in mice reduces mTORC1, S6K, and RPS6 
activity in the liver (46).  In contrast, long-term fasting paradoxically increases hepatic S6K, 
RPS6, and eIF4E activity while simultaneously decreasing eIF2G, phosphorylation of eIF2α, and 
global protein translation (47).  The paradoxical increase in S6K, RPS6 and eIF4E translational 
machinery, but corresponding decrease in eIF2G protein and P-eIF2α expression, during long-
 
	
65 
term fasting may allow for the translational shift from cap-dependent to cap-independent 
translation without requiring phosphorylation of eIF2α.  In agreement to the above findings, 
long-term fasting increases ATF4 expression, but decreases eIF2α expression, in the liver 
(47,48).  Furthermore, long-term thapsigargin treatment increases ATF4 mRNA association with 
heavy polysomes in an eIF2α independent manner, although the nature of the translation has yet 
to be elucidated (49).  Meanwhile, long-term thapsigargin treatment does not increase XBPs 
mRNA association with heavy polysomes suggesting the increase in ATF4 protein translation 
during extended stress conditions is a unique to ATF4 mRNA and does not encompass all UPR 
chaperones.   
The internal ribosome entry site (IRES)-dependent translation is one type of translation 
mechanism that allows for cap-independent translation of mRNAs without requiring the 
phosphorylation of eIF2α (50).  IRESs are complex secondary and tertiary mRNA structures that 
recruit the 40S ribosomal subunit to select mRNAs independent of 5’-end recognition (51).  
Recruitment of the 40S ribosomal subunit independently of 5’cap recognition provides an 
advantage to IRES-containing mRNAs to compete for ribosomes during stress conditions (52).  
Tsai et al. (2014) demonstrated that the PI3K/Akt/mTORC1 axis is able to stimulate protein 
translation through both canonical cap-dependent and IRES-dependent translational mechanisms 
mediated by mTORC1 (53).  It is tempting to suggest that prolonged stress in the liver produced 
during long-term starvation increases ATF4 protein expression through activation of the 
mTORC1/S6K/RPS6/eIF4E signaling axis and selective cap-independent translation of ATF4 
through an identified internal ribosome entry site (IRES) (54).   
Interactions between insulin and glucagon play an important role in regulating hepatic 
metabolic processes.  For example, insulin acts in a dominant manner to suppress the stimulatory 
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effect of glucagon on the transcription of the gluconeogenic genes, PEPCK and glucose-6-
phosphatase (37).  This effect of insulin on gluconeogenic enzyme expression is mediated by the 
Akt/FoxO1 branch of the insulin-signaling pathway (55,56).  Other studies have shown that 
glucagon acts in a dominant manner to suppress the stimulatory effect of insulin on the 
expression of the lipogenic transcription factor, SREBP-1c, and its downstream target genes, 
acetyl-CoA carboxylase and fatty acid synthase (57,58).  This effect of glucagon on SREBP-1c 
expression is mediated at least partially through the mTORC1 branch of the insulin-signaling 
pathway (29,58).  In addition to these two types of antagonistic interactions, our studies 
investigating the regulation of FGF21 expression describe a third type of interaction in which 
glucagon cooperatively interacts with insulin to stimulate ATF4 and FGF21 expression.  
Glucagon also cooperatively interacts with insulin to stimulate hepatic DNA synthesis and cell 
proliferation (59,60) and to increase the activity of Akt and mTORC1 (Figs. 2.7 and 2.9) (27), 
signaling proteins that are required for glucagon and insulin regulation of ATF4 and FGF21 
expression.  The observation that both antagonistic interactions (i.e. SREBP-1c) and cooperative 
interactions (i.e. FGF21) require the presence of mTORC1 suggests that a bifurcation of the 
insulin signaling pathway exists downstream of mTORC1.  
Previous studies by our laboratory have shown that glucagon stimulates hepatic FGF21 
secretion not only by a transcriptional mechanism but also by a posttranscriptional mechanism 
(15).  In the absence of insulin, glucagon regulation of FGF21 expression is solely 
posttranscriptional, as glucagon treatment under this condition stimulates a 3-fold increase in 
FGF21 secretion without a corresponding elevation in FGF21 mRNA abundance.  Results of 
experiments employing selective agonists and/or inhibitors of PKA and EPAC indicate that 
glucagon regulation of FGF21 secretion in the absence of insulin is mediated by both the PKA 
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and EPAC branch of the cAMP pathway.  In contrast, the results of the present study 
demonstrate that glucagon regulation of FGF21 gene transcription in the presence of insulin is 
mediated solely by the PKA branch of the cAMP pathway (Figs. 2.9 and 2.10). Together, these 
findings indicate that the PKA branch of the cAMP pathway acts at both a transcriptional step 
and a posttranscriptional step to control FGF21 secretion, whereas the EPAC branch of the 
cAMP pathway acts only at a posttranscriptional step to control FGF21 secretion.  These 
findings also indicate that cooperative interactions with insulin are restricted to the PKA branch 
of the cAMP pathway. 
Interestingly, only the cAMP analog (db cAMP) and PKA activator (Bnz-6-cAMP), but 
not the EPAC activator (cpTOME), was able to increase ATF4 mRNA abundance in the 
presence of insulin (Fig. 2.9).  These results suggest the PKA branch, but not the EPAC branch, 
of glucagon signaling increases ATF4 mRNA abundance in the presence of insulin.  Inhibition of 
PI3K, Akt, and mTORC did not repress the ability of glucagon plus insulin treatment to induce 
ATF4 mRNA abundance (Fig. 2.8).  Together, these results suggest insulin and PKA signal 
upstream of PI3K to cooperatively stimulate ATF4 gene transcription (Fig. 2.14) but signal 
downstream of PI3K to mediate ATF4 protein expression (Fig. 2.10).  Dey, et al. (2012) showed 
UV treatment suppressed the induction of thapsigargin/P-eIF2α mediated ATF4 protein 
translation by decreasing the ATF4 mRNA pool available for translation, concluding ATF4 
protein translation does occur unless ATF4 mRNA abundance is elevated above basal expression 
(61).  In our study, we propose H89 inhibits ATF4 protein expression by repressing the 
cooperative effects of glucagon plus insulin on ATF4 mRNA abundance.  PKA also 
phosphorylates ATF4 and increases its transactivation to target gene sequences, and that this 
activation is repressed in the presence of H89 (62,63).  Future studies aim to further characterize 
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the transcriptional, translational, and posttranslational role of glucagon plus insulin on ATF4 
expression and activity. 
In contrast to the mechanisms mediating the regulation of FGF21 transcription by 
glucagon plus insulin, CDCA and other bile acids induce FGF21 transcription in part through 
ligand activation of FXR (12).  The results of the present study indicate that two additional 
pathways also contribute to the CDCA induction of FGF21 gene transcription.  One pathway 
involves CDCA stimulation of ATF4 expression via a P-eIF2α-dependent mechanism (Fig. 
2.12B).  The other pathway requires Akt activity and is independent of changes in ATF4 
expression (Fig. 2.12B).  We postulate that that the latter pathway involves the transcription 
factor, nuclear factor E2-related factor 2 (Nrf2), as previous studies have shown that bile acids 
stimulate Nrf2 activity via a PI3K/Akt-dependent mechanism and that Nrf2 induction stimulates 
hepatic FGF21 expression in diabetic mice (64,65).  The ability of CDCA to act through multiple 
signaling pathways to induce FGF21 gene expression provides a means through which CDCA 
can finely control FGF21 production during different conditions. 
Nutritional stress (e.g. starvation) and diseases associated with metabolic syndrome (e.g. 
obesity, type 2 diabetes, nonalcoholic fatty liver disease) stimulate an increase in hepatic FGF21 
expression and serum FGF21 levels (5,7-10).  Elevated FGF21 production in turn mediates 
adaptive changes in insulin sensitivity, growth, circadian behavior, and energy metabolism 
during these conditions (1-7,11).  What is the role of the CDCA/eIF2a/ATF4 pathway and the 
glucagon/insulin/PKA/mTORC1/ATF4 pathway in mediating changes in FGF21 expression 
caused by nutritional stress and metabolic syndrome?  Previous studies have shown that hepatic 
levels of bile acids and serum levels of bile acids, glucagon, and insulin are elevated in obesity, 
type 2 diabetes, and nonalcoholic fatty liver disease (66-68).  Hepatic ATF4 expression, eIFα 
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phosphorylation, PKA activity, and mTORC1 activity are also elevated in obesity, type 2 
diabetes, and nonalcoholic fatty liver disease (69-72).  Recent studies have shown that insulin 
induction of mTORC1 activity during conditions of insulin resistance requires signaling through 
Akt1/2 (73).  These observations provide support for a role of both the CDCA/eIF2a/ATF4 
pathway and the glucagon/insulin/PKA/mTORC1/ATF4 pathway in mediating changes in 
FGF21 expression caused by metabolic syndrome. 
There is evidence that the glucagon/insulin/PKA/mTORC1/ATF4 pathway also plays a 
role in mediating the increase in FGF21 expression caused by starvation.  First, results of 
experiments employing mice lacking hepatic insulin signaling activity (i.e. liver-specific deletion 
of IRS-1 and IRS-2) or glucagon signaling activity (i.e. deletion of the glucagon receptor) have 
shown that both of these pathways are required for the starvation-induced increase in hepatic 
FGF21 expression (14,16,17).  Second, fasting for 48 h causes an increase in hepatic PKA and 
mTORC1 signaling activity and ATF4 protein expression (37,47,48).  Previous studies have 
shown that mTORC1 signaling activity induces both cap-dependent and cap-independent 
translation of selective IRES-containing mRNAs (53).  We hypothesize glucagon plus insulin 
stimulates ATF4 protein expression by enhancing mTORC1-dependent IRES translation of 
ATF4 mRNA (54). 
In conclusion, the results of the present study demonstrate that glucagon and insulin act 
through PKA and mTORC1 to induce the expression of ATF4, a transcription factor that binds 
the FGF21 gene and activates transcription.  This finding in combination with the observation 
that PKA activity, mTORC1 activity, and ATF4 expression are elevated after 48 h of starvation 
supports previous studies demonstrating that both insulin signaling activity and glucagon 
signaling activity are required for the stimulatory effect of starvation on hepatic FGF21 gene 
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expression (14,16,17).  The results of the present study also demonstrate that alterations in ATF4 
expression play a role in mediating the stimulatory effect of CDCA on FGF21 gene expression 
and that eIF2α mediates the increase in ATF4 expression caused by CDCA.  Previous studies 
have shown that the eIF2α/ATF4 pathway mediates the induction of hepatic FGF21 expression 
caused by essential amino acid deficiency (5,22).  Knockout studies performed in mice suggest 
that the eIF2α kinase, general control nonderepressible 2 (GCN2), plays a role a mediating the 
induction in ATF4 and FGF21 expression caused by acute dietary protein restriction (74).  The 
role of GCN2 and other eIF2α kinases in mediating the stimulatory effect of bile acids on FGF21 
expression is the subject of future investigations. 
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Figure 2.1:  Effects of deletions of the 5’-flanking region of the rat FGF21 gene on 
transcriptional activity in the absence and presence of glucagon plus insulin.  Primary rat 
hepatocytes were transiently transfected with a series of plasmids containing fragments of the rat 
FGF21 gene linked to the luciferase (Luc) gene as described under “Experimental Procedures.”  
After transfection, cells were treated with or without 25 nM glucagon (gln) and 50 nM insulin 
(ins) for 24 h.  Cells were harvested, extracts were prepared, and luciferase assays were 
performed.  Left, the constructs used in these experiments.  The number at the left of each 
construct is the 5’-end of FGF21 DNA in nucleotides relative to the transcription initiation site.  
The 3’-end of each construct is +68 bp.  The location of a previously identified FXRE (-1222 to -
1210 bp), PPRE (-1215 to -1203 bp), ChoRE (-72 to -56 bp), and AAREs (-1282 to -1274 bp and 
-140 to -132 bp) are indicated by boxes with different fills or patterns.  Right, luciferase activity 
of cells transfected with the -2940 to +68 bp FGF21 construct and treated with vehicle was set at 
1, and all other activities were adjusted proportionately.  The -fold stimulation by glucagon plus 
insulin was calculated by dividing the luciferase activity for cells treated with glucagon plus 
insulin by that for cells treated with vehicle.  The -fold responses were calculated for individual 
experiments and then averaged.  The results are the means ± S.E. of six experiments.  Different 
superscript letters indicate that the means are significantly (p ≤ 0.05) different. 
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Figure 2.2:  Effects of deletions of the 5’-flanking region of the rat FGF21 gene on 
transcriptional activity in the absence and presence of insulin.  Primary rat hepatocytes were 
transiently transfected with a series of plasmids containing fragments of the rat FGF21 gene 
linked to the luciferase (Luc) gene as described under “Experimental Procedures.”  After 
transfection, cells were treated with 50 nM insulin for 24 h.  Cells were harvested, extracts were 
prepared, and luciferase assays were performed.  Left, the constructs used in these experiments.  
The number at the left of each construct is the 5’-end of FGF21 DNA in nucleotides relative to 
the transcription initiation site.  The 3’-end of each construct is +68 bp.  The location of a 
previously identified FXRE (-1222 to -1210 bp), PPRE (-1215 to -1203 bp), ChoRE (-72 to -56 
bp), and AAREs (-1282 to -1274 bp and -140 to -132 bp) are indicated by boxes with different 
fills or patterns.  Right, luciferase activity of cells transfected with the -2949 to +68 bp FGF21 
construct and treated with vehicle was set at 1, and all other activities were adjusted 
proportionately.  The -fold stimulation by insulin was calculated by dividing the luciferase 
activity for cells treated with insulin by that for cells treated with vehicle.  The -fold responses 
were calculated for individual experiments and then averaged.  The results are the means ± S.E. 
of five experiments. 
 
 
 
 
 
 
 
 
	
73 
Figure 2.3:  Two AAREs in the FGF21 gene confer the stimulatory effect of glucagon plus 
insulin on FGF21 transcription.  Reporter plasmids containing mutations of the AARE1, 
AARE2, AARE1/AARE2, FXRE/PPRE, and/or ChoRE in the context of the -1316 to +68 bp 
FGF21 promoter fragment were transiently transfected into hepatocytes as described in the 
legend of Fig. 1 and under “Experimental Procedures.”  A, native and mutant sequences of the 
AARE1, AARE2, FXRE/PPRE, and ChoRE in the rat FGF21 gene.  The native sequence of each 
regulatory element is indicated in bold letters and the mutated sequence is shown underneath.  
The hexameric half-sites comprising the FXRE and PPRE are indicated by arrows.  B, luciferase 
activity of hepatocytes transfected with wild type and mutant reporter plasmids.  Mutation of the 
AARE1, AARE2, FXRE/PPRE, and ChoRE is indicated by an X through the box designated for 
that element.  The results are the means ± S.E. of six experiments.  Different superscript letters 
indicate that the means are significantly (p ≤ 0.05) different. 
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Figure 2.4:  Glucagon and insulin cooperatively induce ATF4 expression and ATF4 binding 
to AARE1 and AARE2.  A, primary rat hepatocytes were incubated with or without glucagon, 
insulin or glucagon plus insulin.  The abundance of ATF4 mRNA, FGF21 mRNA, and SREBP-
1c mRNA in total RNA was measured after 6 h of treatment.  The abundance of ATF4 protein in 
cell extracts was measured after 12 h of treatment.  The level of ATF4 protein, ATF4 mRNA, 
FGF21 mRNA, and SREBP-1c mRNA in cells incubated with vehicle was set at 1, and the other 
values were adjusted proportionately.  Values are means ± S.E. of seven experiments.  An 
asterisk indicates that the mean is significantly (p ≤ 0.05) higher than any other mean.  B, gel 
mobility shift analyses were performed using nuclear extracts (N.E.) prepared from hepatocytes 
treated with or without glucagon plus insulin for 12 h.  The sequences of 32P-labeled probes 
containing AARE1 or AARE2 are shown in Fig. 2A.  The binding reactions were performed as 
described in “Experimental Procedures.”  Nuclear extracts were incubated with antibodies 
against ATF4 prior to addition of the probe.  Competition analyses were performed by mixing 
the labeled probe with a 5- and 50-fold molar excess of unlabeled probe (self comp.) or a 
competitor DNA containing a mutation of AARE1 or AARE2 (AARE mut comp.).  Positions of 
specific DNA-protein complexes (brackets) and supershifted complexes (SS) are indicated.   
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Figure 2.5:  Knockdown of ATF4 expression suppresses the ability of glucagon plus insulin 
to increase FGF21 mRNA abundance.  Primary rat hepatocytes were transfected with control 
siRNA or siRNA targeting ATF4 as described in “Experimental Procedures.”  After transfection, 
cells were incubated with glucagon and insulin for 12 h.  Cells were then harvested, total RNA 
was isolated, and cellular extracts were prepared.  Top panel, FGF21 mRNA abundance was 
measured in total RNA.  The level of FGF21 mRNA in non-transfected cells incubated with 
vehicle was set at 1, and all other values were adjusted proportionately.  The -fold stimulation by 
glucagon plus insulin was calculated by dividing the FGF21 mRNA abundance of cells treated 
with glucagon plus insulin by that of cells treated with vehicle.  The -fold responses were 
calculated for individual experiments and then averaged.  Values are the means ± S.E. of five 
experiments.  Different superscript letters indicate that the means are significantly (p ≤ 0.05) 
different.  Bottom panel, the abundance ATF4 protein and β-tubulin in cell lysates was measured 
by Western analysis.  These data are representative of five experiments.  
 
 
 
 
 
 
 
 
 
 
 
	
76 
Figure 2.6:  Knockdown of ChREBP expression does not suppress the ability of glucagon 
plus insulin to increase FGF21 mRNA abundance.  Primary rat hepatocytes were transfected 
with control siRNA or siRNA targeting ChREBP as described in “Experimental Procedures.”  
After transfection, cells were incubated with glucagon and insulin for 12 h.  Cells were then 
harvested, total RNA was isolated, and cellular extracts were prepared.  Top panel, FGF21 
mRNA abundance was measured in total RNA.  Middle panel, ChREBP mRNA abundance was 
measured in total RNA. Bottom panel, LPK mRNA abundance was measured in total RNA. The 
level of mRNA in non-transfected cells incubated with vehicle was set at 1, and all other values 
were adjusted proportionately.  The -fold stimulation by glucagon plus insulin was calculated by 
dividing the FGF21, ChREBP, or LPK mRNA abundance of cells treated with glucagon plus 
insulin by that of cells treated with vehicle.  The -fold responses were calculated for individual 
experiments and then averaged.  Values are the means ± S.E. of three-five experiments.  
Different superscript letters indicate that the means are significantly (p ≤ 0.05) different.  
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Figure 2.7:  Inhibition of PI3K, Akt or mTORC1 suppresses the ability of glucagon plus 
insulin to induce FGF21 mRNA abundance and ATF4 protein expression.  Primary rat 
hepatocytes were isolated and incubated in serum-free Medium 199.  At 47 h of incubation, the 
medium was replaced with one of the same composition containing vehicle or the indicated 
concentrations of LY294002 (A), Akti-1/2 (B) or Rapamycin (C).  At 48 h of incubation, 
glucagon and/or insulin was added to the medium and the incubation was continued for 12 h.  
Cells were harvested, total RNA was isolated, and cellular extracts were prepared.  Left panels, 
the abundance of FGF21 mRNA in total RNA and the level of ATF4 protein in total cell lysates 
were measured as described in “Experimental Procedures.”  Values for cells incubated in the 
absence of inhibitor and hormones were set at 1, and the other values were adjusted 
proportionately.  Values are means ± S.E. of four experiments.  Significant differences (p ≤ 0.05) 
between means are indicated by asterisks.  Right panels, the abundance of phosphorylated Akt 
(Ser473) (P-Akt), phosphorylated ribosomal protein S6 (Ser235/236) (P-RPS6), total Akt, and total 
RPS6 in total cell lysates was measured by Western analysis.  These data are representative of 
four experiments. 
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Figure 2.8: Inhibition of PI3K, Akt or mTORC1 does not suppress the ability of glucagon 
plus insulin to induce ATF4 mRNA abundance. Primary rat hepatocytes were isolated and 
incubated in serum-free Medium 199.  At 47 h of incubation, the medium was replaced with one 
of the same composition containing vehicle or the indicated concentrations of LY294002 (A), 
Akti-1/2 (B) or Rapamycin (C).  At 48 h of incubation, glucagon and/or insulin was added to the 
medium and the incubation was continued for 12 h.  Cells were harvested, total RNA was 
isolated, and cellular extracts were prepared. The abundance of FGF21 mRNA in total RNA was 
measured as described in “Experimental Procedures.”  Values for cells incubated in the absence 
of inhibitor and hormones were set at 1, and the other values were adjusted proportionately.  
Values are means ± S.E. of three experiments.  Significant differences (p ≤ 0.05) between means 
are indicated by asterisks.   
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Figure 2.9: Dibutyryl cAMP and 6-Bnz-cAMP mimic the ability of glucagon to stimulate 
FGF21 and ATF4 expression in the presence of insulin.  Primary rat hepatocytes were 
isolated and incubated in serum-free Medium 199.  At 48 h of incubation, the medium was 
replaced with one of the same composition containing glucagon (25 nM), dibutyryl cAMP (100 
µM), 6-Bnz-cAMP (100 µM), cpTOME (5 µM) or vehicle in the absence or presence of insulin 
(50 nM).  After 12 h of incubation, cells were harvested, total RNA was isolated, and cellular 
extracts were prepared.  A, the abundance of FGF21 mRNA and ATF4 mRNA in total RNA and 
the level of ATF4 protein in total cell lysates were measured as described in “Experimental 
Procedures.”  Values for cells incubated with vehicle alone were set at 1, and the other values 
were adjusted proportionately.  Values are means ± S.E. of three experiments.  An asterisk 
indicates that the mean is significantly (p ≤ 0.05) higher compared to that of cells incubated with 
insulin alone.  B, the abundance of ATF4, b-tubulin, phosphorylated Akt (Ser473), phosphorylated 
RPS6 (Ser235/236), total Akt, and total RPS6 in total cell lysates was measured by Western 
analysis.  These data are representative of three experiments.  Quantitation of the signals for 
ATF4 protein is shown in A. C, signaling diagram showing the proteins that are activated by 
dibutyryl cAMP, 6-Bnz-cAMP, and cpTOME.  
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Figure 2.10:  Inhibition of PKA suppresses the ability of glucagon plus insulin to induce 
FGF21 mRNA abundance and ATF4 protein expression.  Primary rat hepatocytes were 
isolated and incubated in serum-free Medium 199.  At 47 h of incubation, the medium was 
replaced with one of the same composition containing H89 (20 µM) or vehicle.  At 48 h of 
incubation, glucagon plus insulin (A) or glucagon alone (B) was added to the medium and the 
incubation was continued for 12 h.  Cells were harvested, total RNA was isolated, and cellular 
extracts were prepared.  The abundance of FGF21 mRNA and PEPCK mRNA in total RNA and 
the level of ATF4 protein in total cell lysates were measured as described in “Experimental 
Procedures.”  Values for cells incubated in the absence of H89 and hormones were set at 1, and 
the other values were adjusted proportionately.  Values are means ± S.E. of three experiments.  
Significant differences (p ≤ 0.05) between means are indicated by the asterisks. 
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Figure 2.11:  CDCA induces ATF4 expression and ATF4 binding to AARE1 and AARE2, 
and knockdown of ATF4 expression suppresses the ability of CDCA to increase FGF21 
mRNA abundance.  A, effect of CDCA on ATF4 expression in primary rat hepatocytes.  The 
abundance of ATF4 protein in total cell lysates and levels of ATF4 mRNA and FGF21 mRNA in 
total RNA were measured after 2 h of treatment with CDCA (100 µM) or vehicle.  The level of 
ATF4 protein, ATF4 mRNA, and FGF21 mRNA, in cells incubated with vehicle was set at 1, 
and the other values were adjusted proportionately.  Values are means ± S.E. of seven 
experiments.  An asterisk indicates that the mean is significantly (p ≤ 0.05) higher compared to 
that of cells treated with vehicle.  B, gel mobility shift analyses were performed as described 
under “Experimental Procedures” using nuclear extracts (N.E.) prepared from hepatocytes 
treated with or without CDCA for 2 h.  Positions of specific DNA-protein complexes (brackets) 
and supershifted complexes (SS) are indicated.  C, effect of knockdown of ATF4 expression on 
CDCA regulation of FGF21 gene expression.  Hepatocytes were transfected with control siRNA 
or siRNA targeting ATF4 as described in “Experimental Procedures.”  After transfection, cells 
were incubated with CDCA for 2 h.  Cells were then harvested, total RNA was isolated, and 
cellular extracts were prepared.  Top panel, FGF21 mRNA abundance was measured in total 
RNA.  The level of FGF21 mRNA in non-transfected cells incubated with vehicle was set at 1, 
and all other values were adjusted proportionately.  The -fold stimulation by CDCA was 
calculated by dividing the FGF21 mRNA abundance of cells treated with CDCA by that of cells 
treated with vehicle.  The -fold responses were calculated for individual experiments and then 
averaged.  The results are the means ± S.E. of five experiments.  Different superscript letters 
indicate that the means are significantly (p ≤ 0.05) different.  Bottom panel, the abundance ATF4 
protein and β-tubulin in cell lysates was measured by Western analysis.  These data are 
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representative of five experiments. 
 
Figure 2.12:  Inhibition of Akt and eIF2α  signaling activity suppresses the ability of CDCA 
to induce FGF21 mRNA abundance.  Primary rat hepatocytes were isolated and incubated in 
serum-free Medium 199.  At 47 h of incubation, the medium was replaced with one of the same 
composition containing 0.3 or 1 µM Akti-1/2 (A), 10 nM ISRIB (B) or vehicle.  At 48 h of 
incubation, CDCA was added to the medium and the incubation was continued for 2 h.  Cells 
were then harvested, total RNA was isolated, and cellular extracts were prepared.  The 
abundance of FGF21 mRNA and ATF4 mRNA in total RNA and the level of ATF4 protein, β-
tubulin, phosphorylated Akt (Ser473), phosphorylated eIF2α (Ser51), total Akt, and total eIF2α in 
total cell lysates were measured as described in “Experimental Procedures.”  Values for cells 
incubated in the absence of inhibitor and hormones were set at 1, and the other values were 
adjusted proportionately.  Values are means ± S.E. of four experiments.  Significant differences 
(p ≤ 0.05) between means are indicated by asterisks. 
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Figure 2.13:  Proposed model for how glucagon, insulin, and CDCA increase hepatic 
FGF21 gene expression and secretion.  Glucagon binding to the glucagon receptor stimulates 
cAMP production resulting in an activation of PKA and EPAC.  Activation of PKA enhances the 
ability of insulin to stimulate the activity of mTORC1, a signaling complex that promotes an 
increase in the ATF4 expression.  ATF4 binds to the FGF21 gene triggering an increase in 
FGF21 transcription and FGF21 secretion.  In combination with EPAC, PKA also stimulates 
FGF21 secretion via a translational and/or posttranslational mechanism that remains to be 
defined.  In addition to glucagon and insulin, CDCA induces FGF21 transcription by increasing 
ATF4 expression.  Here, the elevation in ATF4 expression is mediated by phosphorylated eIF2α.  
CDCA also induces FGF21 transcription by ligand activation of FXR and by an undefined 
mechanism requiring Akt activity.  Results from genetic ablation studies and correlative analyses 
suggest that glucagon, insulin, and bile acid signaling activity plays a role in mediating the 
induction of hepatic FGF21 expression during starvation and conditions related to metabolic 
syndrome (14,16,17,66-68).  Dose-response studies performed in hepatocyte cultures have 
shown that insulin is effective in stimulating FGF21 mRNA abundance at a concentration 
observed in the portal vein during fasted conditions (i.e. 1 nM) (15). 
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Figure 2.14:  Proposed model for how glucagon plus insulin increase hepatic ATF4 
expression.  Glucagon binding to the glucagon receptor stimulates cAMP production resulting in 
the activation of PKA and EPAC.  PKA and insulin signal cooperatively to increase ATF4 
mRNA abundance.  Inhibition of P13K, Akt, and mTORC did not suppress the ability of 
glucagon plus insulin to stimulate ATF4 mRNA suggesting insulin and PKA interact upstream of 
PI3K to modulate ATF4 gene transcription. In contrast, inhibition of PI3K, Akt, and mTORC did 
suppress the ability of glucagon plus insulin to stimulate ATF4 protein expression suggesting 
mTORC is the downstream mediator of ATF4 protein translation.  One hypothesis for mTORC 
mediated ATF4 protein translation is by enhancing IRES-dependent translation of ATF4 mRNA.  
PKA phosphorylates ATF4 and increases its transactivation to target promoters (62,63), 
suggesting PKA posttranslational modification of ATF4 may also contribute to its enhanced 
binding to AAREs on the FGF21 promoter.   
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Figure 2.1:  Effects of deletions of the 5’-flanking region of the rat FGF21 gene on 
transcriptional activity in the absence and presence of glucagon plus insulin.   
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Figure 2.2:  Effects of deletions of the 5’-flanking region of the rat FGF21 gene on 
transcriptional activity in the absence and presence of insulin.   
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Figure 2.3:  Two AAREs in the FGF21 gene confer the stimulatory effect of glucagon plus 
insulin on FGF21 transcription.   
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Figure 2.4:  Glucagon and insulin cooperatively induce ATF4 expression and ATF4 binding 
to AARE1 and AARE2.   
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Figure 2.5:  Knockdown of ATF4 expression suppresses the ability of glucagon plus insulin 
to increase FGF21 mRNA abundance.   
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Figure 2.6:  Knockdown of ChREBP expression does not suppress the ability of glucagon 
plus insulin to increase FGF21 mRNA abundance.   
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Figure 2.7:  Inhibition of PI3K, Akt and mTORC1 suppresses the ability of glucagon plus 
insulin to induce FGF21 mRNA abundance and ATF4 protein expression.   
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Figure 2.8:  Inhibition of PI3K, Akt, and mTORC1 does not suppress the ability of 
glucagon plus insulin to induce ATF4 mRNA abundance. 
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Figure 2.9:  Dibutyryl cAMP and 6-Bnz-cAMP mimic the ability of glucagon to stimulate 
FGF21 and ATF4 expression in the presence of insulin.   
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Figure 2.10:  Inhibition of PKA suppresses the ability of glucagon plus insulin to induce 
FGF21 mRNA abundance and ATF4 protein expression.   
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Figure 2.11:  CDCA induces ATF4 expression and ATF4 binding to AARE1 and AARE2, 
and knockdown of ATF4 expression suppresses the ability of CDCA to increase FGF21 
mRNA abundance.   
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Figure 2.12:  Inhibition of Akt and eIF2α  signaling activity suppresses the ability of CDCA 
to induce FGF21 mRNA abundance.   
 
 
 
 
 
 
 
 
	
97 
 
Figure 2.13:  Proposed model for how glucagon, insulin, and CDCA increase hepatic 
FGF21 gene expression and secretion.   
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Figure 2.14:  Proposed model for how glucagon plus insulin increase hepatic ATF4 
expression.   
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Chapter Three 
 
 
GENERAL DISCUSSION 
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SUMMARY 
 
 
 Obesity rates have increased at an unchecked rate throughout the years leading to the 
development of metabolic syndrome and adverse health outcomes in a significant portion of the 
population. Current therapies for the treatment and prevention of obesity and metabolic 
syndrome are ineffective and/or produce undesirable side effects.  FGF21 is a hormone that 
induced striking reversals of obesity and T2D in both animal and human models.  The use of 
FGF21 as treatment to combat obesity, T2D, and metabolic syndrome offers a fresh alternative to 
current therapies.  
The objective of this study was to determine novel mechanisms mediating the 
endogenous expression of FGF21 in the liver.  We focused on characterizing the molecular 
pathways regulating the ability of glucagon plus insulin and chenodeoxycholic acid to stimulate 
FGF21 gene transcription in primary hepatocytes.  Here we identified ATF4 as a common 
transcriptional mediator that facilitates glucagon plus insulin and CDCA induction of FGF21 
gene expression.  We first employed a reverse genetics approach to discover cis-acting sequences 
on the FGF21 promoter that confer gene regulation under glucagon plus insulin treatment.  Next, 
we identified ATF4 as the primary transcription factor that binds to, and activates, the FGF21 
promoter after glucagon plus insulin and CDCA treatment.  We then used loss-of function and 
gain-of-function techniques to identify the PI3K/Akt/mTORC1 insulin-signaling pathway and 
the cAMP/PKA glucagon-signaling pathway as regulatory mediators for both ATF4 and FGF21 
expression during glucagon plus insulin treatment.  Furthermore, we uncovered Akt and eIF2α as 
the key mediators of ATF4 and FGF21 expression during CDCA treatment. 
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One important finding of this study is the discovery that ATF4 facilitates the positive 
cooperatively between glucagon and insulin on target gene transcription. To date, ATF4 
represents the only known transcription factor shown to mediate the positive interaction between 
glucagon and insulin in the liver.  Glucagon and insulin have been shown to signal 
synergistically to mediate selective cellular processes in the liver (1-3).  Zhao, et al. (2000) 
showed that glucagon and insulin work cooperatively to increase the phosphorylation of the 
downstream metabolic mediator, Akt, and this induction might be due to PKA inhibition of 
phosphatases that dephosphorylate the Akt kinase (4).  Meanwhile, additional studies suggest the 
glucagon and insulin synergism occurs upstream of PI3K.  For example, glucagon potentiates 
insulin induction of the insulin tyrosine receptor kinase’s ability to uniquely increase 
phosphorylation of downstream targets (5).  This selectivity suggests glucagon may potentiate 
the ability of insulin to active unique pathways downstream of the insulin tyrosine kinase while 
simultaneously repressing others.  My data suggests glucagon plus insulin signal both upstream 
and downstream of PI3K (Figs. 2.13 and 2.14).  Glucagon plus insulin treatment cooperatively 
increased phosphorylation of Akt and P-S6 ribosomal subunit, and that PI3K, Akt, and mTORC1 
inhibition repressed this effect (Fig. 2.7).  These results suggest glucagon and insulin signal 
cooperatively downstream of PI3K.  Surprisingly, inhibition of the PI3K/Akt/mTORC1 axis did 
not repress the ability of glucagon plus insulin to increase ATF4 mRNA, suggesting the 
cooperatively observed between the two hormones also lies upstream of PI3K at the insulin 
receptor (Fig. 2.8).  Additional studies need to be performed to elucidate the role of the insulin 
receptor tyrosine kinase in mediating the effects of glucagon plus insulin on ATF4 and FGF21 
expression.  
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FUTURE DIRECTIONS 
 
A second important finding of this study is the discovery that nutritional signals mediate 
mTORC1 driven cap-dependent translational of target mRNAs during non-stress cellular 
conditions, but also that nutritional signals may also mediate mTORC1 translational activity to 
cap-independent translation of IRES-containing metabolic mRNAs during prolonged stress 
induced states.  The high glucagon to insulin concentrations present during the portal vein during 
starvation may represent one type of metabolic stimuli that may induce the switch of 
mTORC1mediated cap-dependent to cap-independent translation of mRNAs.  Starvation 
paradoxically increases the activities of hepatic S6K, RPS6, and eIF4E translational machineries, 
but decreases eIF2G, phosphorylation of eIF2α, and general protein translation (6).  In addition 
to starvation, protein free diets are a second type of dietary condition that increases 
PI3K/mTORC1 activity in primary livers during low nutrient availability (7).  These findings 
suggest that, similar to mode of action for eIF2α phosphorylation, the switch from mTORC1 
mediated cap-dependent to cap-independent translation allows for a decrease in global protein 
translation while simultaneously allowing for the translation of selective mRNAs during stress 
conditions.  Starvation and prolonged ER stress increase ATF4 expression in an unknown eIF2α-
independent mechanism (6,8,9).  We hypothesize the increase in ATF4 protein translation 
observed during starvation may be mediated through cap-independent mTORC1 mediated 
translation.  
Additional nutritional factors have been shown to follow the cap-dependent to cap-
independent translational switch depending on dietary conditions.  For example, insulin receptor 
biosynthesis in pancreatic β-cells is cap-dependently translated during high glucose conditions 
but switches to cap-independent, IRES-dependent translation during starvation (10,11). The 
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selective upregulation of insulin receptor mRNA translation during starvation is believed to 
increase cellular insulin sensitivity during low nutrient availability.  These results suggest low 
nutrient availability may switch mTORC1 translation from cap-dependent to cap-independent 
translation of IRES containing mRNAs.  IRES-dependent translation effectively out-competes 
the cap-dependent mRNA translation for access to translational machinery during stress, 
allowing for the select increase in critical nutrient adaptation factors over global protein 
translation. ATF4 mRNA contains an IRES that can be translated during cap-independent 
conditions (12).  The potential role for mTORC1 to mediate IRES-dependent translation of 
mRNAs during different dietary conditions is currently an unexplored area in the biomedical 
sciences. 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
 
	
110 
REFERENCES 
 
1. Bucher, M. L., and Swaffield, M. N. (1975) Regulation of hepatic regeneration in rats by 
synergistic action of insulin and glucagon. Proc Natl Acad Sci U S A 72, 1157-1160 
2. Giacca, A., Fisher, S. J., McCall, R. H., Shi, Z. Q., and Vranic, M. (1997) Direct and 
indirect effects of insulin in suppressing glucose production in depancreatized dogs: role 
of glucagon. Endocrinology 138, 999-1007 
3. Kimura, M., and Ogihara, M. (1997) Proliferation of adult rat hepatocytes in primary 
culture induced by insulin is potentiated by cAMP-elevating agents. European Journal of 
Pharmacology 327, 87-95 
4. Zhao, A. Z., Shinohara, M. M., Huang, D., Shimizu, M., Eldar-Finkelman, H., Krebs, E. 
G., Beavo, J. A., and Bornfeldt, K. E. (2000) Leptin induces insulin-like signaling that 
antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 275, 11348-11354 
5. Ito, Y., Uchijima, Y., Ariga, M., Seki, T., Takenaka, A., Hakuno, F., Takahashi, S. I., 
Ariga, T., and Noguchi, T. (1997) Interaction between cAMP-dependent and insulin-
dependent signal pathways in tyrosine phosphorylation in primary cultures of rat 
hepatocytes. Biochem. J. 324 ( Pt 2), 379-388 
6. Anand, P., and Gruppuso, P. A. (2005) The Regulation of Hepatic Protein Synthesis 
during Fasting in the Rat. J. Biol. Chem. 280, 16427-16436 
7. Toyoshima, Y., Tokita, R., Ohne, Y., Hakuno, F., Noguchi, T., Minami, S., Kato, H., and 
Takahashi, S. (2010) Dietary protein deprivation upregulates insulin signaling and 
inhibits gluconeogenesis in rat liver. Journal of molecular endocrinology 45, 329-340 
8. Sokolović, M., Sokolović, A., Wehkamp, D., van Themaat, E. V. L., de Waart, D. R., 
Gilhuijs-Pederson, L. A., Nikolsky, Y., van Kampen, A. H. C., Hakvoort, T. B. M., and 
Lamers, W. H. (2008) The transcriptomic signature of fasting murine liver. BMC 
Genomics 9, 528 
9. Guan, B.-J., Krokowski, D., Majumder, M., Schmotzer, C. L., Kimball, S. R., Merrick, 
W. C., Koromilas, A. E., and Hatzoglou, M. (2014) Translational Control during 
Endoplasmic Reticulum Stress beyond Phosphorylation of the Translation Initiation 
Factor eIF2α. J. Biol. Chem. 289, 12593-12611 
10. Fred, R. G., Sandberg, M., Pelletier, J., and Welsh, N. (2011) The human insulin mRNA 
is partly translated via a cap- and eIF4A-independent mechanism. Biochemical and 
Biophysical Research Communications 412, 693-698 
11. Spriggs, K. A., Cobbold, L. C., Ridley, S. H., Coldwell, M., Bottley, A., Bushell, M., 
Willis, A. E., and Siddle, K. (2009) The human insulin receptor mRNA contains a 
functional internal ribosome entry segment. Nucleic Acids Res 37, 5881-5893 
12. Chan, C. P., Kok, K. H., Tang, H. M., Wong, C. M., and Jin, D. Y. (2013) Internal 
ribosome entry site-mediated translational regulation of ATF4 splice variant in 
mammalian unfolded protein response. Biochim Biophys Acta 1833, 2165-2175 
 
